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Abstract 
Type 2 diabetes impacts upon quality of life. Quality of life is lower in diabetes 
than in the general population but what happens to quality of life over the first 
years following the diagnosis is less clear. In addition, Type 2 diabetes is 
associated with depression and other psychological problems.  
Diet and physical activity are cornerstones of the management of diabetes. 
Despite the multitude of benefits these lifestyle changes have, adherence to 
these interventions is poor with people with Type 2 diabetes experiencing 
numerous barriers to dieting and exercising. A possible reason for the poor 
adherence could be that these interventions result in a reduction in quality of life 
or wellbeing, or reduced satisfaction with their treatment. 
The aim of this thesis is determine the effects of diet and physical activity 
interventions on quality of life, wellbeing and treatment satisfaction in newly 
diagnosed Type 2 diabetes, as well as to explore what changes in quality of life 
and wellbeing occur in first years following diagnosis. 
Chapter 1 reviews the current evidence of the changes in quality of life and 
wellbeing that occur in Type 2 diabetes over time, their associations and how 
they are effected by lifestyle interventions. 
Chapter 2 describes the Early ACTvity in Diabetes randomised control trial of 
lifestyle interventions in early Type 2 diabetes from which the dataset originates. 
Chapter 3 demonstrates lifestyle interventions delivered in newly diagnosed 
Type 2 diabetes improve treatment satisfaction and do not affect quality of life 
and wellbeing. It also demonstrates quality of life and wellbeing are not 
associated with response. 
Chapter 4 demonstrates quality of life decline slowly over the first six years 
following diagnosis of Type 2 diabetes, and that this change is likely part of the 
normal progression of Type 2 diabetes. It also demonstrates wellbeing does not 
change over this period and that lifestyle interventions have no lasting effect on 
quality of life or wellbeing. 
Chapter 5 brings together the main findings of this thesis and their clinical 
implications, and provides direction for future work. 
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Introduction 
This thesis is composed of five chapters. 
Chapter 1 aims to provide a thorough background to the project with a review of 
relevant literature and description of the project’s aims and hypotheses. 
Chapter 2 aims to provide an overview of the Early ACTivity In Diabetes (Early 
ACTID) randomised control trial; the study that provides the data for this project. 
It will use the CONSORT guidance as a framework and provide more in-depth 
information on the questionnaires used. 
Chapter 3 aims to assess the impact of diet and diet and physical activity 
interventions on treatment satisfaction, quality of life, illness perception and 
wellbeing in newly diagnosed Type 2 diabetes using data from the Early ACTID 
randomised control trial. 
Chapter 4 aims to assess the long-term impact of lifestyle interventions on 
treatment satisfaction, quality of life, illness perception and wellbeing over up to 
five years following completion of the Early ACTID trial using data from the 
follow up study ACTID Plus. It will also aim to assess the changes that occur 
over time in quality of life, illness perception and wellbeing over the first 6 years 
following diagnosis of Type 2 diabetes in this cohort. 
Chapter 5 aims to discuss the principal findings of this project, where they fit 
with current literature, their implications, and future directions for research in 
this field.  
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1.1 Type 2 diabetes 
1.1.1 Definition 
Type 2 diabetes is a disease of high blood glucose due to a combination of 
pancreatic beta cell dysfunction and insulin resistance in target organs (1). It is 
characterised by hyperinsulinaemia, insulin resistance and eventual beta cell 
failure. On the other hand, Type 1 diabetes is an autoimmune destruction of the 
pancreatic beta cells leading to severe insulin deficiency. The distinction 
between Type 1 and Type 2 diabetes was made as early as 500-600 BC by 
Sushrata and Charaka. Type 1 was described as the diabetes of youth and 
Type 2 was the diabetes of obesity (2). To this day, Type 2 diabetes is more 
common at older ages and Type 1 diabetes is mainly considered a disease of 
childhood. However, increasing obesity and better identification of Type 1 
diabetes in older adults means this distinction is more blurred than previously 
thought (3). Type 2 diabetes accounts for 90% of all diabetes, is on the rise,  
and comes with complications that result in significant morbidity and mortality 
(4).  
1.1.2 Epidemiology 
Type 2 diabetes is a growing problem worldwide, with the final quarter of the 
20th century seeing the incidence and prevalence of Type 2 diabetes quadruple. 
The estimated global prevalence for adults between the ages of 20-70 in 2017 
is 1 in 11 (425 million), with 1 in 2 of these people undiagnosed. The major 
contributing factors to this increase are thought to be calorie-rich diets and 
increasingly sedentary lifestyles (4). 
1.1.3 Pathophysiology 
Fundamentally the hyperglycaemia of Type 2 diabetes is the result of 
dysregulation of the feedback loop involving beta-cells and insulin sensitive 
tissues (Figure 1). 
Stimulation of beta-cells results in the release of insulin. Insulin acts on insulin-
sensitive tissues to mediate the uptake of glucose, amino acids and fatty acids, 
thus reducing blood glucose. The insulin-sensitive tissues then feedback their 
insulin requirement to the beta-cells by a hitherto unknown mechanism. If 
insulin resistance is present, beta-cells increase production of insulin to 
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increase uptake of glucose to return to euglycaemia. However, if these beta-
cells are unable sufficiently increase insulin production in response to this, the 
hyperglycaemic state persists (5). 
The reasons behind the development of this dysregulation are likely to be a 
combination of genetic and environmental factors (Figure 2). At the moment the 
insulin resistance caused by obesity accounts for up to 80% of Type 2 diabetes, 
and the development of insulin resistance as a result of obesity is thought to 
progress more rapidly to Type 2 diabetes in those with genetic risk for beta-cell 
dysfunction (4,5). 
1.1.4 Complications 
Persistent hyperglycaemia leads to severe microvascular and macrovascular 
complications. Microvascular complications include retinopathy that can lead to 
blindness, nephropathy that can lead to renal failure, and peripheral neuropathy 
that can lead to severe motor, sensory and autonomic dysfunction. Retinopathy 
affects 20 per cent of people with Type 2 diabetes and across all of forms of 
diabetes is responsible for 1280 new cases of blindness every year (6,7). 
Nephropathy accounts for 11% of deaths in people with Type 2 diabetes (8). 
Neuropathy is common across all types of diabetes and leads to 7000 diabetes 
related amputations each year in the UK (9). In addition, up to 80% of people 
having amputations die within five years (10). Improving glycaemic control 
significantly reduces the rates of these microvascular complications (1).  
Cardiovascular disease is the major macrovascular complication of diabetes. A 
large scale meta-analysis showed the presence of diabetes doubled the risk of 
coronary heart disease, more than doubled the risk of ischaemic stroke and 
increased the risk of death from other vascular disease by 73% (11). However, 
it is less clear what impact improved glycaemic control has on macrovascular 
complications.  
Despite improved knowledge and treatment of Type 2 diabetes its complications 
are still responsible for huge morbidity and mortality. Treatment of diabetes 
related complications cost healthcare systems vast sums of money, with 
diabetes-related foot ulcers and amputations costing £1 of every £140 spent on 
the NHS (9). 
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Figure 1 – Dysregulation of glucose homeostasis by beta-cells and insulin-
sensitive tissues. (A) Normal blood glucose levels maintained by action of 
insulin on insulin-sensitive tissues. The amount of insulin produced is 
determined by the insulin sensitivity of target tissues. (B) Insulin resistance in 
insulin-sensitive tissues leads to increased insulin production by beta-cells but 
normal blood glucose levels are maintained. (C) Beta-cells unable to produce 
sufficient insulin in response to insulin resistance in target tissues. This leads to 
inadequate glucose uptake and high blood glucose levels. Image taken from 
Kahn et al. (5) 
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Figure 2 – Factors leading to the development of obesity and Type 2 diabetes. 
Taken from Kahn et al. (5) 
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1.1.5 Treatment 
Type 2 diabetes is managed by a combination of diet, exercise and 
pharmacological therapies (Figure 3). The first step is to give general diet and 
activity advice. In the UK, this is often given in primary care, soon after 
diagnosis. Diet and physical activity are the cornerstone of diabetes prevention 
and management. With obesity underlying 80% of cases of Type 2 diabetes it 
makes sense that lifestyle changes resulting in weight loss are effective in both 
preventing and treating Type 2 diabetes. Lifestyle changes have been shown 
conclusively to prevent the development of diabetes in those with impaired 
glucose tolerance (12,13). In those with Type 2 diabetes, lifestyle changes 
reduce body weight, improve glycaemia, insulin sensitivity, blood pressure, 
lipids, endothelial function and may improve morbidity and mortality (14–21). 
Considerable weight loss through intensive dietary interventions has even been 
shown to achieve diabetes remission in overweight people with Type 2 diabetes 
(22). 
Adherence to lifestyle changes in Type 2 Diabetees is poor. The recent 
Time2DoMore survey showed adherence to dietary changes was just 51% and 
adherence to physical activity advice 40%. This was a multinational survey of 
652 adults with diabetes and 337 treating physicians assessing clinical inertia in 
diabetes treatment. With this in mind an increasing body of work is looking at 
the barriers preventing patients from adhering to lifestyle interventions (23).  
This work revealed lifestyle changes are a significant burden for patients. A 
survey of US patients found moderate dietary changes to be a greater burden 
than oral glucose lowering agents. Furthermore, strict dietary changes were 
rated as equally burdensome to insulin therapy. Focus groups in this study cited 
reasons such as cost, small portion sizes and quality of life/lifestyle issues (24). 
Encouraging people to increase their physical activity, particularly in those who 
are most sedentary is just as troublesome. Sweating and physical discomfort 
were the main barriers identified by a 2009 systematic review. In addition, the 
feeling of being too fat to exercise was common and in keeping with this, adults 
of normal weight experience fewer barriers to exercise (25). 
The next step is medical therapy with metformin, it reduces hepatic glucose 
output, improves insulin sensitivity, and stimulates GLP-1 secretion. Importantly, 
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it is also weight neutral and lowers HbA1c by around 10-20 mmol/mol. No single 
drug has been identified as the optimum second line treatment, as the current 
advice is to add one of any of the following drug classes; sulfonylureas, DPP-IV 
inhibitors, SLGT-2 inhibitors, thiazolidinediones, or an injectable GLP-1 receptor 
agonist (26).  
The main aim of treatment is to improve blood glucose control to prevent the 
development of complications. The key marker of blood glucose control in 
diabetes is glycosylated haemoglobin (HbA1c) as this is the most closely 
associated marker with complications in key studies (27,28). HbA1c is a 
measure of the proportion of haemoglobin which is glycated by glucose in the 
bloodstream. As the life of a red blood cell is around 12 weeks the measure 
provides evidence of the glycaemic status of the individual over the previous 3 
months. An HbA1c level of 48mmol/mol (6.5%) or more is diagnostic of the 
disease, and patients may well be asymptomatic at this time. Those with an 
HbA1c level of 43-48mmol/mol are defined as having impaired glucose 
tolerance or ‘prediabetes’ and have a high risk of progressing to Type 2 
diabetes. Therefore, HbA1c is the key outcome in clinical practice and in most 
interventional trials in diabetes.  
Despite oral medical therapy, many people with Type 2 diabetes progress to 
requiring insulin treatment, which comes with an array of complications and 
carries a lot of stigma with patients. Insulin treatment requires patients to closely 
monitor their glucose levels, self-inject insulin, and carries the risk of 
hypoglycaemia. Fear of hypoglycaemia and worry about self-management and 
complications are common in insulin-treated patients (29). Therefore, avoiding 
progression to insulin therapy with effective early treatment through lifestyle 
changes is paramount.  
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Figure 3 – NICE Guideline for medical management of Type 2 diabetes. 
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1.2 Quality of Life 
1.2.1 What is quality of life?  
An individual’s quality of life can be described as a global status of a person’s 
perception of their own physical, mental, social and emotional wellbeing. As 
such, if you were to assess the quality of life of two people who objectively had 
an identical health status their quality of life could be different (30).  
It can be argued that research based on patient-reported wellbeing, quality of 
life and satisfaction is more relevant to patients than any biomedical outcome. 
The WHO definition of health states that health is not only the absence of illness 
but instead a feeling of physical, mental and social wellbeing (31). 
1.2.2 How is it measured? 
Historically quality of life research has primarily been interview-based but 
increasingly it is reported using standardised questionnaires. These often have 
multiple domains answered on standardised scales, e.g. a Likert Scale from 
Strongly Agree to Strongly Disagree (32). 
There are two basic approaches to assessing quality of life in this way. Some 
measures assess general quality of life and other assess disease-specific 
quality of life. Each approach comes with its own benefits. Generic measures 
have the advantage of being applicable across different diseases and giving a 
more complete view of an individual’s quality of life, usually across numerous 
domains. Disease-specific measures have the advantage of assessing specific 
problems people with a particular disease may face. For example, in diabetes 
research the Diabetes Quality of Life (DQOL) questionnaire considers the 
impact of hypoglycaemia, self-monitoring of blood sugars, and self-injection of 
insulin (30,32). 
Although quality of life is fundamentally the most important outcome for 
patients, doing research into it can be difficult. Results are subject to within-
individual variation as well as between-individual variation. Furthermore, as 
quality of life is affected by so many factors is difficult to attribute causal 
relationships. However, disease-specific questionnaires make this easier by 
being more specific to the condition and its treatment.  
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It is also difficult to create a questionnaire that is reliable enough to return 
similar results in similar people but responsive enough to illustrate changes in 
quality of life at different times. For this reason, new questionnaires are 
validated in different populations to ensure their reliability as a research tool. It 
is also important to determine the clinical significance of changes in 
questionnaire scores. Knowing what degree of change in a particular 
questionnaire score represents a noticeable difference for that person in the 
real world is fundamental to assessing quality of life.  
Many questionnaires that assess quality of life focus on an individual’s health 
status. Health status can be defined as the presence of biological of 
psychological dysfunction, symptoms and functional status (33). For this reason 
they can fail to pick the impact of these other aspects of an individual’s life and 
may under report differences in quality of life. 
Evaluation of the psychometric properties of questionnaires is focused on two 
major properties; reliability and validity (34). Reliability (how repeatable the 
results are) can be assessed in numerous ways. The two most common ways 
reported are test-retest reliability and Cronbach’s alpha of internal consistency. 
Test-retest reliability is simply the correlation between the results when the 
questionnaires is given to the same individuals on two separate occasions. 
Internal consistency measured using Cronbach’s alpha is more complex. 
Cronbach’s alpha is the degree to which the items of the questionnaire are 
correlated. The more similar the items the higher value of alpha. It is important 
to note the great influence the number of items has, with fewer items resulting in 
a lower value of alpha. A maximum value for alpha of 0.9 has therefore been 
advocated and a value higher than this suggests redundant items. As with 
reliability, there are numerous type of validity (how well the results represent the 
truth). The most commonly reported are construct validity and concurrent 
validity. Construct validity is the extent to which the questionnaire measures the 
intended psychological construct. Concurrent validity is the extent to which the 
results are correlated with similar questionnaires. For example, a measure of 
life satisfaction would be expected to correlate negatively with a questionnaire 
assessing depression. 
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Table 1 – Description of popular patient-reported outcome measures used in 
diabetes. Adapted from Speight et al. (33) 
Measure Description 
Measures of Health Status 
EQ-5D A generic measure that primarily assesses health status. Part one is a 
health index created from five items: Mobility, Self-Care, Pain, Usual 
activities, and Anxiety/depression. Part two is a visual analogue scale 
used to indicate an individual’s overall perception of their health. 
SF-36 A generic measure of health status. Composed of 36 items and reported 
as 8 domains: Bodily Pain, Mental Health, Role-emotional, Role-physical, 
physical functioning, social functioning, vitality, and general health.  
Generic measures of quality of life 
WHOQOL Generic measure of quality of life composed of 100 items assessing 25 
different aspects of quality of life across themes including physical, 
psychological, social and emotional quality of life. 
WHOQOL-
BREF 
Shortened version of WHOQOL, Composed of 26 items that are reported 
on four subscales: physical health, psychological health, social 
relationships, and environment. Two items assess overall quality of life 
and general health. 
Diabetes specific measures of quality of life 
ADDQOL ADDQOL is a diabetes specific measure of quality of life. It is made up of 
18 items. Scores are weighted according to which domains an individual 
feels are most important. Covers various aspects of quality of life 
including; working life, social life, family life, sex life holidays and leisure, 
and enjoyment of food. Tow summary items measure current quality of 
life and diabetes-dependent quality of life. 
DQOL The first measure of diabetes specific quality of life developed for use in 
the Diabetes Control and Complications Trial (DCCT). Composed of four 
subscales that measure satisfaction, impact, social worry and diabetes 
worry. 
Measures of wellbeing 
BDI The Beck Depression Inventory is composed of 21 items. Each item is a 
list of four statements arranged in increasing severity about a particular 
symptom of depression, including biological symptoms. 
HADS Hospital Anxiety and Depression Scale is composed of 14 items: 7 
assess depression and 7 assess anxiety 
PAID A diabetes specific measure of emotional distress caused by diabetes 
and its treatment composed of 20 items. 
W-BQ 12 A generic measure of psychological wellbeing. 12 items are scored on 3 
subscales of positive wellbeing, negative wellbeing and energy. 
W-BQ 28 A measure of generic and disease specific psychological wellbeing. 28 
items are scored on 7 subscales; 3 assess diabetes specific positive 
wellbeing, negative wellbeing, and stress; the other 4 assess general 
positive wellbeing, negative wellbeing, energy and stress. 
Measures of treatment satisfaction 
DTSQ A diabetes specific measure of treatment satisfaction. Composed of 8 
items; six assess satisfaction. This covers: satisfaction, convenience, 
flexibility, understanding, likelihood of recommending, likelihood of 
continuing. The remaining two items assess perceived frequency of 
hypo/hyperglycaemia  
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1.2.3 How is it measured in diabetes? 
A recent review has brought together the different measures popularly used to 
assess quality of life and other outcomes in diabetes (33). These can be divided 
into measures that predominantly assess health status, those that 
predominantly assess diabetes specific quality of life, and those that assess 
generic quality of life. Table 1 summarises these measures.  
1.2.4 What happens to quality of life in diabetes? 
People with Type 2 diabetes report poorer quality of life than those without the 
disease. However, they do have better quality of life than people with most 
other chronic diseases. 
Unlike Type 1 diabetes, there seems to be little impact of diagnosis of Type 2 
diabetes on quality of life. Early studies suggested quality of life dipped initially 
at diagnosis but soon returned to normal levels (35–37). Since then, the best 
evidence of the change in quality of life that occurs following diagnosis comes 
from the American Diabetes Prevention Program (DPP) and its long term follow 
up study, the Diabetes Prevention Program Outcomes Study (DPPOS) (38). 
DPP was a landmark randomised control trial comparing the ability of an 
intensive lifestyle intervention (ILS), metformin treatment (MET) and placebo 
(PLB) to prevent the development of Type 2 diabetes in those with impaired 
glucose tolerance. Despite the interventions, some patients went on to develop 
Type 2 diabetes. This provided a unique opportunity to analyse changes in 
quality of life from around the time of diagnosis to up to 6 years after. Quality of 
life was assessed using the SF-36 questionnaire, a widely used measure of 
generic health-related quality of life. Subscale scores in different health domains 
were combined to produce two composite scores. The Physical Component 
Summary (PCS) and Mental Component Summary (MCS). Score across all 
domains were used to produce an overall score of health state called SF-6D. In 
all participants diagnosed with diabetes, PCS and SF-6D scores declined over 
the course of the trial. MCS scores were stable in all arms except for an initial 
fall in participants in the ILS arm but this difference did not persist. These 
results suggest there is a gradual decline in quality of life in the first years 
following a diagnosis of Type 2 diabetes. The fact it declined in all trial arms 
suggests this is part of the natural progression of the disease. 
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Figure 4 – Quality of life results from the DPPOS, split into SF-6D score of 
overall health, Mental Component Summary (MCS) of SF-36, and Physical 
Component Summary (PCS) of SF-36. Taken from Marrero et al. (38). 
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1.2.5 What is quality of life in diabetes associated with? 
In long duration Type 2 diabetes, declining quality of life is seen with the 
development of both microvascular and macrovascular complications. The 
United Kingdom Prospective Diabetes Study (UKPDS) was a landmark study 
which aimed to answer the fundamental question of whether improved blood 
glucose control reduces the incidence of complications, and whether different 
treatments have specific advantages or disadvantages (39). Quality of life was 
measured in a cohort of over 5000 participants using the generic EuroQol - 5 
Dimensions (EQ-5D) measure of health status. It found in the year following the 
development of a microvascular and macrovascular complication quality of life 
declined significantly. However, they saw no effect of different treatments on 
quality of life.  
In addition a large scale survey of people with Type 2 diabetes in a primary care 
setting found the reduction in quality of life and was primarily related to the 
presence of microvascular complications, heart disease, depression and high 
number of diabetes medications (40). The survey took place in the US, reported 
on 909 individuals, and used a generic measure of health related quality of life 
called the Health Utility Index. There were also weaker associations between 
reduced quality of life and older age, female sex, lower education level and 
diabetes duration.  
1.2.6 How do lifestyle interventions affect quality of life? 
Effects in newly-diagnosed Type 2 diabetes 
Participants receiving the intensive lifestyle intervention in the American 
DPP/DPPOS experienced a worse decline in quality of life than those in the 
metformin or placebo treated arms (Figure 4) (38). In addition, participants in 
the ILS arm experienced an immediate decline in MCS score following 
diagnosis but their trajectory returned to one similar to the metformin and 
placebo treated arms. This reduction may have been due to disappointment at 
having developed diabetes despite their efforts to prevent it. Interestingly, 
participants in the ILS arm who remained diabetes-free experienced an 
improvement in PCS score in the first year but then declined gradually over the 
trial, suggesting they were able to delay this decline. 
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However, results of the DESMOND study suggest behavioural lifestyle 
interventions can be delivered without reducing quality of life. The British 
Diabetes Education and Self-Management for Ongoing and Newly Diagnosed 
(DESMOND) study was multicentre cluster randomised control trial assessing 
the effects of a 6-hour comprehensive group-based lifestyle advice and 
education intervention in newly diagnosed Type 2 diabetes (41). Practices 
assigned to control were resourced to provide an enhanced usual care with 
contact time with healthcare staff equivalent to those in the intervention arm.  
Resources were used by practices as they saw fit within their usual care 
routine. Quality of life was assessed using the WHOQOL-BREF. There was no 
difference in subscale scores between the interventions and control arms after 
one year of follow up. There was also no difference between the groups in 
diabetes distress as assessed by the PAID questionnaire, and no difference in 
depression as assessed by the HADS. Illness perception was measured by the 
revised Illness Perception Questionnaire. Results showed those in the 
intervention group had a greater understanding of their illness and seriousness, 
a better perception of its duration, and a better understanding of their ability to 
influence the course of their illness. It is important to note the enhanced usual 
care delivered to the control arm may have contributed to the lack of difference 
between arms. 
Effects in established Type 2 diabetes 
The Action for Health in Diabetes (Look AHEAD) study showed those in the 
lifestyle intervention arm experienced a slower decline in quality of life (42). This 
was a landmark study in Type 2 diabetes that aimed to assess the long-term 
impact of a weight loss lifestyle intervention on cardiovascular morbidity and 
mortality. It included more than 5000 participants who were cluster randomised 
to the intensive lifestyle intervention (ILI) group or a diabetes support and 
education (DSE) control arm. The intensive lifestyle intervention targeted 
aggressive weight loss of 10% through dietary changes, exercise prescription 
and physical activity advice, as well as weight lowering medications such as 
Orlistat (43). Patient-reported outcome measures were recorded during the trial, 
including quality of life measured using the SF-36. There was a significant 
difference between the groups in the Physical Component Summary (PCS). 
Although scores in both groups declined during the trial, the rate of decline was 
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slower in the ILI group compared to the DSE group. There appeared to be no 
effect of the intervention on the Mental Component Summary (MCS), with 
scores remaining relatively stable in both groups throughout the trial. These 
results suggest an intensive lifestyle intervention may mitigate the decline in 
physical function seen with ageing. 
Effects of physical activity and diet types 
Evidence of the effect of different exercise types on quality of life, psychological 
wellbeing, depressive symptoms, and anxiety is limited and provides conflicting 
results (44). The most recent systematic review looking at the effects of 
exercise on quality of life and wellbeing reported in 2013. Of 20 RCTs included, 
16 studies assessed quality of life. Of the 16 RCTs assessing quality of life; 6 
assessed the effect of aerobic training, 4 the effect of resistance training and 10 
the effect of combined training. Aerobic training improved physical health and 
sleep in one RCT but there was no change in quality of life in all the other 
studies. Resistance training showed highly conflicting results, with one short 
duration study showed improved quality of life in favour of the intervention group 
but another longer duration study showed a significant, albeit small, difference 
in favour of control. Combined training again returned mixed results with 3 
studies showing training improved quality of life, 1 showing training reduced 
quality of life, and 6 showed no change in quality of life. 
A direct comparison between supervised exercise and physical activity advice 
showed supervised exercise and physical activity advice resulted in improved 
quality of life compared to physical activity advice alone. The Italian Diabetes 
and Exercise Study (IDES) was a large randomised trial with glycaemic control 
as the primary outcome. Quality of life was measured using SF-36. 
Improvements were seen in both PCS and MCS scores, with the greatest effect 
size seen in PCS. Particular improvements were seen in role limitations due to 
physical functioning, bodily pain, and general health perception. However, in 
this study the amount of contact time between each of the interventions was 
vastly different, being higher in the supervised arm, and this may explain the 
difference. 
The effect of dietary changes alone on quality of life in people with Type 2 
diabetes is a very under-researched area. This was highlighted in the 2007 
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been a meta-analysis or systematic review assessing the impact of different 
dietary changes on quality of life in people with Type 2 diabetes. However, a 
recent systematic review and meta-analysis of the use of carbohydrate 
restriction in the management of Type 2 diabetes analysed quality of life 
changes in studies specifically comparing low carbohydrate diets (LCD) and 
high carbohydrate diets (HCD) (45). Quality of life was measured in just 5 of the 
10 studies included in the meta-analysis. In the two studies that assessed 
generic HRQoL using the SF-36, there was no difference in MCS score, but 
overall PCS scores declined more in those receiving the LCD intervention 
compared to a HCD. In the three other studies that used other questionnaires, 
there was no difference in scores between arms, including one trial that used 
the disease-specific Diabetes-39 (D-39) tool. 
In the context of obesity, a systematic review of weight loss through dietary 
changes has reported quality of life is improved by weight loss, but significant 
levels of weight loss are required. At the time of the review, evidence at 
randomised control trial level was lacking. However since then the Diabetes 
Remission Clinical Trial (DiRECT) has reported (22). The DiRECT study 
assessed the ability of a primary care-led low-calorie diet intervention to achieve 
remission of Type 2 diabetes in overweight people. It is the first and only 
randomised control trial of a dietary intervention with the primary outcome of 
remission of diabetes. Remission was defined as a sustained return of HbA1c to 
non-diabetic levels (<48mmol/mol), after at least two months without diabetes 
medication. The intervention involved a weight loss induction phase using a 
low-calorie formula diet for 3-5 months, followed by structured re-introduction of 
food over the 2-8 weeks, with subsequent ongoing weight management. 
Diabetes and antihypertensive medications were stopped on day 1 of the 
intervention. This intervention resulted in diabetes remission in 46% or 
participants. Remission was also heavily associated with weight loss across the 
whole study. 86% of people who achieved weight loss of ≥15kg achieved 
remission and just 7% of those who lost 0-5kg. As well as achieving a higher 
rate of remission, individuals in the intervention arm experienced an 
improvement in quality of life as measured by EQ-5D VAS of 6.4 points (95% CI 
2·5, 10·3; p=0·0012).  
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1.2.7 How was it measured in this project? 
In this study quality of life was measured using the EuroQoL- 5 Dimensions 
(EQ-5D) (see Appendix 1). The EQ-5D is a widely used measure of preference 
based health-related quality of life. It has been used in populations across the 
world, across a number of different diseases. The EQ-5D is composed of two 
parts. Part one is a questionnaire with 5 items (dimensions): Mobility, Self-Care, 
Usual activities, Pain/discomfort, and Anxiety/depression. Each dimension is 
answered on a 3 level scale. 1 represents no difficulty, 2 represents some 
difficulty, 3 represents severe difficulty (e.g. unable to mobilise). The resulting 
set of responses is converted to an index score of overall health by an algorithm 
using population-specific coefficients. Part two of the questionnaire is a Visual 
Analogue Scale (VAS) where participants are asked place a point on a line of 0-
100 where they think they are on the line, with 0 representing the worst 
imaginable health state and 100 representing the best imaginable health state.  
The use of the EQ-5D in adults with Type 2 diabetes has recently been 
reviewed (46). This identified 54 relevant publications and aimed to summarise 
the validity, reliability and responsiveness of the EQ-5D in diabetes, and provide 
a catalogue of scores of various subgroups and complications. It found the 
spread if values of health index value in keeping with what was expected, with 
end-stage renal failure and severe diabetic neuropathy pain at the lower end of 
health index and comorbidities such as treated hypertension at the higher end. 
Overall, it found the EQ-5D displayed construct, convergent and discriminant 
validity. Reliability ranged from good to excellent and is was similarly responsive 
as other measures like the SF-12 and SF-36. However, several studies noted a 
ceiling effect. This is a well-known limitation of the EQ-5D and led to the 
development of a 5-level version. 
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1.3 Wellbeing 
1.3.1 What is wellbeing? 
Wellbeing is different to quality of life in that it focuses on mental health and by 
extension mental illness. This includes constructs such as affect, self-esteem 
and subjective wellbeing, as well depression and anxiety (47).  
1.3.2 How is it measured in diabetes?  
Similar to quality of life, wellbeing is commonly assessed using multiple-item 
questionnaires. These measures are required to both valid and reliable and can 
be divided into those that measure general wellbeing and those that measure 
diabetes specific wellbeing. The most commonly used measures in diabetes are 
given in Table 1.  
1.3.3 How does Type 2 diabetes affect wellbeing? 
Type 2 diabetes is associated with a variety of psychological problems. The two 
major associated psychological conditions are depression and psychological 
distress. 
Type 2 diabetes and depression are heavily associated. People with type 2 
diabetes are 24% more at risk of developing depression than non-diabetic 
individuals (48). The prevalence of depression with Type 2 diabetes is almost 
double that of people without diabetes (18% vs 10%) (49). In addition, 
comorbidity with depression seems to be related to the burden of a diagnosis of 
chronic disease, with significantly lower risk of depression in patients with 
impaired glucose metabolism or undiagnosed diabetes compared to those with 
a diagnosis of Type 2 diabetes (50).  
Type 2 diabetes also often results in significant emotional distress. A recent 
systematic review has reported on disease specific “diabetes distress” (51). 
Diabetes distress describes the broad array of distinct emotional concerns 
surrounding the experience of living with diabetes, a chronic and progressive 
disease. This can include feeling overwhelmed by the responsibility of 
managing their own condition through self-monitoring and lifestyle changes, as 
well as worry over possible future progression to insulin and/or development of 
complications. They may also fear hypoglycaemia or suffer feeling of guilt or 
shame relating to obesity and/or lifestyle choices (51,52). The findings of the 
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systematic review were that diabetes distress was a significant issue estimated 
to affect 36-46% of people with Type 2 diabetes. It is more common in women 
than men and more common in those with depressive symptoms. 
1.3.4 What effects does wellbeing have on Type 2 diabetes? 
Diabetes and depression is thought to be a bi-directional relationship, with those 
suffering depressive symptoms more likely to experience self-neglect, and 
perhaps more likely to have unhealthy lifestyles predisposing them to the 
development of Type 2 diabetes (53). Depression was also associated with 
poorer glycaemic control in a meta-analysis albeit with a small effect size (54).  
There is also evidence of poor diet and exercise habits in people with Type 2 
diabetes and persistent or worsening depressive symptoms (55). In addition, 
Sumlin et al. performed a systematic review of the association between 
depression and adherence to diet and physical activity lifestyle changes (56). 
They pooled data from 7266 participants. Twenty-one descriptive studies were 
identified and showed a negative relationship between depression and 
adherence to diet and physical activity lifestyle changes. Only two of six 
interventional studies assessed this relationship and had conflicting evidence. 
The reviewers noted there was likely a true association however RCT-level 
evidence is both limited and conflicting. 
Diabetes distress, like depression, is associated with poorer glycaemic control. 
Both could be explained by a direct effect through dysregulation of stress 
hormones, or by depressive symptoms and distress both leading to poor self-
care (52,57). 
1.3.5 How does treatment affect wellbeing in Type 2 diabetes? 
A 2013 systematic review of exercise on quality of life and wellbeing found four 
studies that examined the effect on depression (44). Results were inconclusive. 
Two short duration studies of aerobic exercise found no difference in depressive 
symptoms between intervention and control. A further study of home-based 
combined aerobic and resistance training interventions again found no 
difference in depressive symptoms. However, these studies were all limited by 
short duration (less than 8 weeks). There was however one longer duration 
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study (16 weeks) which showed resistance exercise reduced depressive 
symptoms. 
The same review identified the effect of aerobic training on other aspects of 
wellbeing including anxiety (44). Wellbeing in all studies was assessed using 
the W-BQ 12 or its parent questionnaire the W-BQ 22. There was conflicting 
evidence as some shorter duration studies of aerobic and resistance exercise 
found improvements in wellbeing and reduced anxiety. However, a longer 
duration study found no difference between intervention and control after 
aerobic, resistance and combined aerobic and resistance exercise (58). 
Since this review, the landmark Look AHEAD trial has reported its wellbeing 
results. It assessed depressive symptoms using the Beck Depression Inventory 
over 8 years of follow up and found the intensive lifestyle intervention (ILI) 
reduced the risk of developing depression by 15% compared with control (DSE) 
(42).  
1.3.6 How was it measured in this project? 
Wellbeing was assessed in two domains; self-esteem and life satisfaction. 
Life satisfaction 
Life satisfaction was assessed using Diener’s Satisfaction with Life Scale 
(SWLS). It is a measure developed to assess global satisfaction with life, a key 
component of subjective wellbeing. Subjective well-being is composed of three 
separate components, positive affect, negative affect and life satisfaction. Whilst 
the first two components refer to the emotional side of subjective wellbeing, 
overall life satisfaction is a much more cognitive process. Life satisfaction is 
defined as a “global assessment of a person’s quality of life according to his/her 
chosen criteria” (59). 
The scale is composed of 5 items on a 7 point Likert scale form Strongly Agree 
to Strongly Disagree. The 5 items are: 
• In most ways my life is close to ideal 
• The conditions of my life are excellent 
• I am satisfied with my life 
• So far I have gotten the important things I want in life 
• If I could live my life over, I would change almost nothing. 
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The five items are all positive worded so a sum score of life satisfaction can be 
produced by adding scores together. 
A 1985 review of questionnaires assessing subjective wellbeing found the 
SWLS compared favourably with other instruments (60). It had excellent test-
retest reliability, high internal consistency despite being only 5 items, and 
converged well with other measures. However, a vulnerability to social 
desirability bias was highlighted.  
Overall, it is one of the most popular scales used to measure life satisfaction. It 
has been validated in a huge variety of populations, including those with 
diabetes. 
Self-Esteem 
Self-esteem was measured using the Rosenberg Scale of Self-esteem (RSES). 
It is one of the most widely used instruments in the history of psychology. 
Originally designed for adolescents it has been validated and used extensively 
across adults of all ages. The scale is composed of 10 items; 5 positive 
statements and 5 negative statements. Originally designed as Guttman Scale 
with complex scoring, many have since used a sum score, reversing the 
negatively worded items. This approach has been adopted by most people 
since (61,62).  
The 10 items of the scale are: 
• I feel that I am a person of worth, at least on an equal plane with others. 
• I feel that I have a number of good qualities 
• All in all, I am inclined to think I am a failure. 
• I am able to do things as well as most other people. 
• I feel I do not have much to be proud of. 
• I take a positive attitude toward myself. 
• On the whole, I am satisfied with myself. 
• I wish I could have more respect for myself. 
• I certainly feel useless at times. 
• At times I think I am no good at all. 
Each item is rated from Strongly Agree to Strongly Disagree on a 4-point scale. 
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The scale has excellent test-retest reliability and internal consistency. It 
demonstrates concurrent, predictive and construct validity. It correlates well with 
other measures and has negative associations with expects factors such as 
anxiety and depression (62). 
1.4 Treatment Satisfaction 
1.4.1 What is treatment satisfaction? 
Treatment satisfaction is a global assessment of an individual’s experience of 
their treatment across all aspects. As treatments are very specific to a disease, 
disease specific measures are generally favoured. 
1.4.2 How is it measured in diabetes? 
Much like with quality of life and wellbeing treatment satisfaction is normally 
assessed using validated questionnaires. The most widely used is measure is 
the almost universally adopted Diabetes Treatment Satisfaction Questionnaire 
(DTSQ) (Table 1) (63). It is the treatment satisfaction tool recommended by the 
World Health Organisation (WHO) and International Diabetes Federation (IDF) 
(64). 
1.4.3 How does treatment satisfaction vary across different 
diabetes treatments? 
The reason treatment satisfaction is very important in diabetes is treatments are 
often judged almost entirely on their ability to reduce HbA1c. However, 
treatments can have the same HbA1c response but can be hugely different 
experiences for people receiving the treatment. For this reason treatment 
satisfaction in diabetes has recently been reviewed (65). 
An example of this scenario is in rapid-acting insulin analogues. Whilst they 
result in a similar change in HbA1c as treatment with human insulin, the 
increased flexibility and reduced risk of hypoglycaemia results in far greater 
treatment satisfaction (66). Similar improvements in treatment satisfaction 
despite no difference in HbA1c have been seen in studies comparing long-
acting insulins to neutral protamine Hagedorn (NPH) insulin. This phenomenon 
is not restricted to insulin analogues, and has been seen in oral medications 
including incretin-related agents, SGLT-2 inhibitors, once weekly DPP-4 
inhibitors and fixed dose combination tablets.  
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Lifestyle interventions have also been shown to improve treatment satisfaction. 
The Diabetes X-PERT study assessed the impact a lifestyle and self-
management intervention in those with established Type 2 diabetes. Those in 
the intervention arm experienced improved treatment satisfaction compared to 
control (67). 
1.4.4 Which factors are associated with changes in treatment 
satisfaction? 
The authors of the review described above have attempted to answer this very 
question (65,68). Their study in a Japanese secondary-care setting found a 
number of factors associated with treatment satisfaction. They found improved 
satisfaction was associated with lower treatment intensity, with those treated 
through lifestyle changes alone experiencing the highest satisfaction and those 
on insulin treatment experiencing the lowest satisfaction. This was an expected 
finding although there is evidence of improved satisfaction with insulin treatment 
in poorly controlled diabetes (69). 
Importantly they found treatment satisfaction was not related entirely to the 
intervention prescribed and care delivery was understandably very important. 
Treatment satisfaction was strongly associated with dissatisfaction with waiting 
times, satisfaction with consultation time, satisfaction with the attending doctor 
and satisfaction with the overall hospital visit. Satisfaction with the attending 
doctor was the most strongly associated factor highlighted that the treatment 
itself it not always the most important in determining satisfaction. 
Interestingly, satisfaction with diabetes treatment was also associated with 
improved adherence and reduced dropout from treatment. The association with 
improved adherence was seen with diabetes medication and diet and physical 
activity therapies.  
HbA1c was not associated with treatment satisfaction, a finding in keeping with 
some other studies (66). However, a large Dutch cohort study assessing quality 
of life and treatment satisfaction in people living with Type 2 diabetes revealed 
people with higher HbA1c levels, younger people, and people on insulin therapy 
were less satisfied with their treatment. There were also modest but statistically 
significant associations with EQ-5D Index and EQ-5D VAS (70). 
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1.4.5 How was it measured in this project? 
The Diabetes Treatment Satisfaction Questionnaire (DTSQ) is a disease-
specific measure of satisfaction with treatment developed in 1988 that has 
become widely used in diabetes research across the world (63). It is composed 
of 8 items. 6 items if the scale assess subjects satisfaction with treatment 
across six areas; satisfaction, convenience, flexibility, understanding, likelihood 
to recommend, likelihood to continue. The other two items relate to how often 
subjects experience hypoglycaemia or hyperglycaemia. 
The DTSQ demonstrates internal consistency, test-retest reliability, as well as 
content, convergent and concurrent validity. Although responsive to change, 
many have identified a ceiling effect and this led to the development of the 
DTSQ Change Version (DTSQc) to be used in tandem with the DTSQ with 
repeated-measure study designs (71). 
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1.5 Summary 
1.5.1 What we know 
Type 2 diabetes is a common chronic illness that can be successfully treated 
with lifestyle changes. Quality of life and wellbeing are affected by Type 2 
diabetes and as such they are important treatment outcomes. Type 2 diabetes 
results in a reduction of quality of life, this decline being associated with the 
development of complications, associated depression, or the requirement of 
large numbers of medications. Despite improving a multitude of clinical 
outcomes, adherence to lifestyle interventions is poor. 40-51% of people with 
Type 2 diabetes are non-adherent. In addition, recent surveys have identified a 
number of barriers to dieting and exercising encountered by people with Type 2 
diabetes, particularly those who are obese. These include the burden of dieting 
on quality of life, as well as physical discomfort, sweating or shame/stigma 
experienced when exercising. 
1.5.2 What remains unclear 
Trials of lifestyle interventions have provided conflicting results of their effects 
on quality of life, particularly early on the disease when they are most likely to 
be offered. The limited evidence suggests a modest decline in quality of life, 
particularly physical quality of life. However, other studies have shown no 
change in quality of life. Moreover, is some studies of people with established 
diabetes have shown improved quality of life and wellbeing as a result of 
lifestyle changes. Therefore, the effects of these interventions on wellbeing and 
quality of life need clarification. 
Secondly, comorbid depression is associated with poor adherence to lifestyle 
interventions but the degree to which individuals’ wellbeing and quality of life 
contribute to the poor adherence seen remains unclear. 
Thirdly, what happens to quality of life and wellbeing over the first years 
following diagnosis of Type 2 diabetes prior to the development of complications 
is unclear. Evidence of the changes in quality of life that occur in this time is 
limited to one study and little is known about wellbeing over this period.  
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1.5.3 What this project aimed to add 
This project used existing patient reported outcome measure data from the 
Early ACTivity In Diabetes (Early ACTID) randomised control trial (72). The trial 
compared dietary advice, diet plus physical activity advice and usual care in 
order to determine whether the addition of physical activity advice to dietary 
advice warrants the additional training of staff it would require. The main 
findings were firstly that dietary and physical activity interventions close to 
diagnosis improved HbA1c, use of diabetes medication, weight, waist 
circumference, and insulin resistance compared to usual care. Secondly, the 
addition of physical activity advice to dietary advice did not confer any additional 
benefit and so extensive retraining that would be required to deliver this 
intervention on a large scale is not justified. 
I will use patient-reported outcome measure data from Early ACTID to answer 
three broad research questions of: 
1. How do treatment satisfaction, quality of life and wellbeing change during 
the first 6 years following diagnosis of Type 2 diabetes? 
2. What is the effect of lifestyle interventions on treatment satisfaction, 
quality of life and wellbeing in newly diagnosed Type 2 diabetes? 
3. Are treatment satisfaction, quality of life and wellbeing associated with 
response to lifestyle interventions in Type 2 diabetes? 
The project hypotheses were: 
1. There is a modest decline in quality of life over time in all trial arms. 
2. Treatment satisfaction is higher in the intervention groups compared to 
control. 
3. Self-esteem and life satisfaction are improved by lifestyle interventions 
4. Higher baseline self-esteem and/or life satisfaction is associated with 
greater improvements in HbA1c and weight loss. 
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2.1 The Early ACTID Trial 
This thesis used existing patient-reported outcome measures data from the 
Early ACTivity In Diabetes (Early ACTID) randomised control trial. This Chapter 
will first describe the reasons behind the trial, and explain in full how it was 
performed using the CONSORT guidance as a reference. It will then provide a 
summary of the main findings of the trial and a spotlight on the patient-reported 
outcome measures used in the trial; how they are scored, and what the scores 
indicate, 
The aim of the Early ACTID trial was to determine whether providing physical 
activity alongside dietary advice offered additional benefits above those seen 
when dietary advice is given alone in newly diagnosed Type 2 diabetes.  At the 
time of the trial, people with new type 2 diabetes were offered one-to-one 
dietary advice, attendance at an education day, or both. The physical activity 
advice given in these interventions was usually very general as few healthcare 
workers are trained in this field. In order to justify additional training of large 
numbers of staff, a clear additional benefit of physical activity advice would 
need to be shown (72). 
2.1.1 Trial Design 
The Early ACTID trial was a multicentre, parallel group randomised control trial 
of lifestyle interventions in newly diagnosed Type 2 Diabetes. It had three arms; 
usual care, an intensive dietary intervention, and an intensive diet plus physical 
activity intervention. 
2.1.2 Participants 
Inclusion Criteria 
1. Type 2 Diabetes as defined by 
a. BMI greater than 25 
b. No ketosis 
c. No significant weight loss prior to diagnosis  
2. Between 5-8 months from clinical diagnosis of Type 2 diabetes 
Exclusion Criteria 
1. Age over than 80 at diagnosis 
2. HbA1c greater than 10% 
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3. Blood pressure greater 180/100mmHg 
4. LDL greater than 4 units 
5. Weight greater than 180kg 
6. Individual already receiving a maximum dose of sulphonylurea 
7. Current diagnosis of Unstable Angina 
8. Myocardial Infarction within last 3 months 
9. Unable to increase physical activity level 
10. Individual pregnant or is of childbearing age and not surgically sterile or 
not using a form of contraception. 
Withdrawal Criteria 
1. The individual becomes pregnant, as evident by a positive pregnancy 
test 
2. The investigator feels it is in the subject’s best interest to be withdrawn 
Setting 
Participants were recruited through primary care and direct advertising via four 
recruitment centres. 
• Taunton and Somerset NHS Trust, covering Somerset 
• United Bristol Healthcare NHS Trust, covering North Somerset 
• North Bristol NHS Trust, covering North Somerset 
• Gloucestershire Hospitals NHS Trust, covering Gloucestershire 
Location 
The trial took place across 7 sites in South West England. 
• Taunton and Somerset NHS Trust Musgrove Park Hospital 
• Weston General Hospital 
• Cheltenham General Hospital 
• Gloucestershire Royal Hospital 
• United Bristol Healthcare 
• Frenchay Hospital 
• Southmead Hospital 
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2.1.3 Interventions 
Timeline of Visits 
The timeline of visits and differences between numbers of visits by participants 
in each arm during the Early ACTID trial is given in Table 1.  
Table 1 – Timeline of visits in Early ACTID 
Time 
(wks) 
Visit Action Standard 
care 
Diet 
alone 
Diet plus 
activity 
-6 1 Consent and screening ü ü ü 
-4 2 Fitness test ü ü ü 
-2 3 Consent qualitative study and baseline 
measurements  
ü ü ü 
  Randomisation data is collated & prepared prior to visit 4 
0 4 Clinical review & randomisation to 
treatment arm 
ü ü ü 
2 5 Nurse visit  ü ü 
4 6 Nurse visit  ü ü 
6 7 Nurse visit  ü ü 
10 8 Nurse visit  ü ü 
14 9 Nurse and Dietitian visit  ü ü 
20 10 Nurse visit  ü ü 
26 11 6 month measurements ü ü ü 
28 12 6 month fitness test ü ü ü 
32 
 
13 
 
Doctors and dietitian (nurse for standard 
care arm) review visit 
ü ü ü 
38 14 Nurse visit  ü ü 
42 15 Nurse and dietitian visit  ü ü 
46 16 Nurse visit  ü ü 
52 17 12 month measurements ü ü ü 
54 18 12 month fitness test ü ü ü 
58 19 Doctor and dietitian review – discharge 
plan 
ü ü ü 
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Usual Care 
Participants in the usual care arm received doctor, dietary and nursing advice at 
baseline. They were then seen at 6 and 12 months by both a doctor and nurse.  
In the dietary session, dietitians gave standard advice about diet and provided 
the patients with a patient information sheet detailing the recommended diet for 
those in the two intervention arms. Nurses provided general advice about 
exercise and monitoring of urine (or blood where applicable). Participants were 
also given the contact details of the Early ACTID team and were able to 
organise sessions with a nurse if they had problems regarding the management 
of their disease.  
Intensive Dietary Intervention 
Participants in the intensive dietary intervention received usual care as well as a 
comprehensive dietary intervention with nine additional sessions with a nurse or 
dietitian over the 12 months (Table 1). 
The primary goal of the intervention was for participants to achieve a weight 
loss of 10% of their initial body weight and maintain that weight loss throughout 
the trial. The recommended pace of this weight loss was 0.5-1kg per week to 
produce 5% weight loss in approximately 12 weeks. 
This weight loss would be achieved by the establishment of a hypo-energetic 
diet, based on an energy deficit of approximately 500kcal within the context of 
general guidelines for a healthy diet. 
Sessions included advice on 
• Healthy eating 
• Meal frequency 
• Sugar 
• Special diabetic foods 
• Alternative sweeteners 
• Fats 
• Carbohydrates 
• Fibre 
• Alcohol 
• Salt 
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• Management of illness 
• Understanding food and nutrition levels  
• Eating out 
• Shopping tips 
Sessions were based around the setting of personalised goals. Participants 
recorded a food diary for 4 days prior to each session. Using this participant and 
dietitian discussed potential changes and came up with agreed personal 
targets. 
Individuals who wanted to achieve greater than 10% weight loss were 
encouraged to do so provided their resultant BMI would be greater than 24. In 
addition, weight loss of greater than 2kg per week was not advised due to 
safety. Individuals who struggled to meet the weight loss target set personalised 
goals that were more achievable, but it was important they remained 
challenging.  
A key aim of the intervention was to not only achieve weight loss, but to 
maintain it over the longer term. Therefore, the sessions aimed to provide with 
the necessary skills and behaviours to main their weight successfully over in the 
long term. 
Intensive Dietary and Physical Activity Intervention 
Participants in the diet and physical activity arm received all components of the 
usual care and intensive dietary intervention, as well as a physical activity 
advice intervention 
The physical activity intervention aimed to achieve and maintain a 700kcal 
additional energy expenditure per week through moderate-to-vigorous physical 
activity (equivalent to 150 minutes walking). It was described to participants as 
half an hour of brisk walking at least 5 days each week for ease of 
understanding. This goal was applied to all participants, independent of their 
existing physical activity level. 
The physical activity level was increased step-by-step over 5 weeks. During the 
first week participants were encouraged to do something active 3 to 4 days per 
week. In the subsequent weeks the activity level was increased to 60, 90, 120 
and finally 150 minutes per week. The physical activity target was a minimum 
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target. Participants who wished to do more exercise were encouraged to do so. 
Participants who were already active had to add a further 150 minutes of activity 
to meet their goal. In addition, those who were seasonally active were 
encouraged to spread their physical activity consistently over the months of the 
trial. 
Participants measured their activity levels using hip worn activity monitors and 
recoding an activity log. Participants were requested to keep their activity log 
daily and record the time of day and reading when the device was put on and 
then when it was taken off at the end of the day. They were also requested to 
record the reading before and after walking periods and the duration of the 
activity. Data was used to monitor physical activity levels achieved and to 
identify the presence of absence of any compensatory sedentary behaviour. 
A key strategy of the intervention was to empower participants with the 
confidence to exercise. This was achieved by practitioner and participant setting 
negotiated, realistic and achievable targets. This was supported by participants 
self-monitoring of their progress towards the target.  
Adjustments to the intervention were made where participants did not wish to 
choose walking as their activity. The options to choose alternative exercise 
forms was open and those who wished to do more vigorous exercise such as 
running, had the duration of their activity tailored towards achieving the 700kcal 
weekly energy expenditure target. For those participants who found the physical 
activity targets difficult, personalised goals were made, as well as the provision 
of input from a fitness trainer and/or discounted gym memberships. 
Control of other factors 
To attempt to negate the potential impact of increased contact time, the study 
was designed to ensure participants in both intervention arms received the 
same amount of contact time. In both intervention arms, one half of each 
session was allocated to discussion of dietary changes. In the dietary 
intervention arm, the other half of the session was dedicated to patient-led 
discussion of lifestyle topics of their choice. In contrast, for those in the dietary 
and physical activity intervention arm the other half was dedicated to the 
physical activity advice. 
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To attempt to negate the potential impact of medication changes, steps were 
made to limit changes that occurred. During the study the trial team took over 
the care of all participants and any changes to medication were made according 
to a standardised protocol. In addition all doctors making the changes were 
blinded to arm allocation. Figures 1-4 display this protocol in full. In addition to 
this, ethical approval was given for no changes to diabetes and blood pressure 
medications to be made during the first 6 months to enable evaluation of the 
true effect of the interventions. 
 
 
49 
 
Figure 1 - Diabetes Medication Protocol for first 6 months of Early ACTID 
 
Figure 2 - Diabetes Medication Protocol for second 6 months of Early ACTID 
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Figure 3 – Blood pressure medication protocol for first 6 months of Early ACTID 
 
Figure 4 – Blood pressure medication protocol for second 6 months of Early 
ACTID 
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2.1.4 Outcomes 
Primary Outcomes 
• Glycaemic Control as measured by HbA1c at 6 months 
• Systolic and diastolic blood pressure at 6 months 
Secondary Outcomes 
• Glycaemic control as measured by HbA1c at 12 months 
• Systolic and diastolic blood pressure at 12 months 
• Fasting lipid profile (Total cholesterol, HDL, LDL and TG) 
• Insulin resistance (measured by HOMA) 
• Insulin secretion (measured by HOMA) 
• Weight (kg) 
• BMI 
• Body composition 
• Waist and hip circumference  
• Cardiovascular fitness (measured by mile walk test) 
• Amount of diabetes, blood pressure and Lipid medication required 
• Activity measured by Actigraph at baseline, 6 and 12 months 
• Questionnaires 
o Physical Activity 
§ PARQ 
§ Stage of change towards exercise 
§ Self-efficacy towards exercise 
§ Process of change 
§ Social support for physical activity scale 
§ Decisional balance 
§ Outcome expectations for exercise 
o Sleep 
§ Epworth Sleepiness Scale 
§ The Sleep Habit questionnaire 
o Wellbeing 
§ Satisfaction with Life Scale (SWLS) 
§ Rosenberg Self-Esteem Scale 
§ Euroqol – 5 Dimensions (EQ-5D) 
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§ Diabetes Treatment Satisfaction Questionnaire (DTSQ) 
§ Brief Illness Perception Questionnaire (BIPQ) 
o Diaries 
§ 1 week sleep diary 
§ 4 day food diary 
2.1.5 Sample size  
Originally the planned sample size was 750 participants, allocated in a 1:1:1 
ratio to diet, diet and physical activity and usual care. With HbA1c and blood 
pressure the primary outcomes, this sample size was determined in order to be 
able to detect between group differences in these parameters. The standard 
deviation of HbA1c among people with diabetes is reported at 1.87% and the 
minimum clinically important difference is reported at 0.5%.This is equivalent to 
an effect size of 0.27 SD. For blood pressure this equates to 4.5mmHg in 
systolic and 2.3mmHg in diastolic blood pressure. Due to high retention and 
slower than expected recruitment, this was amended to 546 participants split in 
a 5:5:2 ratio (216 in each intervention arm and 86 in the control arm). The 
original sample size provided 90% power, but the revised minimum target of 
546 participants split in a 5:5:2 ratio provided 80% power with a 5% two-sided 
alpha to detect differences of 0.27 SD between intervention arms, and power to 
detect a difference of 0.4 SD between an intervention arm and usual care. This 
allowed for 5% of data missing. 593 participants ended up being recruited. 99 
were assigned usual care, 248 the diet intervention, and 246 the diet and 
activity intervention. It was decided it would have been unfair not to randomise 
people who had been consented after the target sample size of 546 had been 
reached. 
2.1.6 Randomisation 
Randomisation was performed by computer generated allocation. Participants 
were assigned in a 2:5:5 ratio to intensive dietary intervention, intensive dietary 
and physical activity intervention and usual care. Allocations remained 
concealed until participants attended visit 4 when they saw a dietitian who 
phoned the trial coordinator to retrieve the allocation code. Allocation was 
stratified by centre and minimised by age, sex, fitness, route into study and 
blood pressure..  
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2.1.7 Blinding 
The nature of the intervention meant nurses, dietitians and participants were 
unable to be blinded. Doctors were blinded. Assessments were done by nurses. 
2.1.8 Statistical Methods 
As per CONSORT guidance the primary outcomes were reported using an 
intention-to-treat analysis. 
In this project questionnaire data was analysed in two ways. 
• To assess the between arm differences during the trial, T-tests of change 
from baseline score were used. Significance was achieved at p<0.0167 
after Bonferroni correction. Participants were included in this analysis if 
they completed all items of at least one questionnaire at baseline and 
after 12 months. This is described in full in the methods section of 
Chapter 3. 
Analysis of the trends in quality of life during long-term follow up treated the 
participants as a single cohort and assessed longitudinal changes using 
multilevel mixed effects linear regression. This is described in full in the 
methods section of Chapter 4. 
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2.2 ACTID Plus 
ACTID Plus was the long-term follow up study of Early ACTID participants. 
Following completion of Early ACTID, participants were contacted and re-
consented to enter ACTID Plus. ACTID Plus followed up participants with 
annual visits for 5 years following completion of the program (6 years post-
randomisation). This is shown in Table 2. 
Table 2 – Timeline of visits in ACTID Plus 
Follow-up phase 
104 20 Re-consent,  2 year measurements ü ü ü 
156 21 3 year measurements ü ü ü 
208 22 4 year measurements ü ü ü 
260 23 5 year measurements ü ü ü 
310 24 6 year measurements ü ü ü 
 
Where participants did not wish to attend in person some agreed to share their 
GP records and be followed up annually through primary care. The same 
measurements were recorded at each follow up point as in Early ACTID. 
There were three major aims of the ACTID Plus study. 
• The first aim was assess whether diet and diet plus activity intervention 
had lasting beneficial effects compared to usual care in terms of weight, 
glycaemia, blood pressure, lipid profile, insulin resistance, and 
medication requirement. 
• The second aim of ACTID Plus was to assess whether these 
interventions had lasting beneficial effects compared to usual care in 
terms of eating patterns, physical activity habits, and patient-reported 
outcome measures. 
• The third and final main aim of ACTID Plus was to determine whether 
these effects, if seen, are greater in the diet and physical activity arm 
than in the diet only arm of the trial. 
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2.3 Wellbeing Measures in Early ACTID and 
ACTID Plus 
At each measurement visit of Early ACTID and ACTID Plus, participants were 
asked to complete paper copies of 5 patient-reported outcome measures that 
assessed the impact of diabetes on their wellbeing. The exact document 
provided to participants at each visit is given as Appendix 1. This section 
outlines the scoring of each of the measures used in Early ACTID and ACTID 
Plus. 
2.3.1 Diabetes Treatment Satisfaction Questionnaire (DTSQ) 
The Diabetes Treatment Satisfaction Questionnaire (DTSQ) is a disease-
specific measure of satisfaction with treatment. It is composed of 8 items. 6 
items of the scale assess subjects satisfaction with treatment across six areas; 
satisfaction, convenience, flexibility, understanding, likelihood to recommend, 
likelihood to continue. The other two items relate to how often subjects 
experience hypoglycaemia or hyperglycaemia. Each item is answered on a 7-
point Likert scale (0-6). A sum score of overall satisfaction is calculated by 
adding together the scores of the six satisfaction items (73). 
2.3.2 EuroQol – 5 Dimensions (EQ-5D) 
The EQ-5D is a widely used measure of preference based health-related quality 
of life. The EQ-5D is composed of two parts.  
Part one is a questionnaire with 5 items (dimensions): Mobility, Self-Care, Usual 
activities, Pain/discomfort, and Anxiety/depression. Each dimension is 
answered on a 3 level scale. 1 represents no difficulty, 2 represents some 
difficulty, 3 represents severe difficulty (e.g. unable to mobilise). The resulting 
set of responses is converted to an index score of overall health by an algorithm 
using population-specific coefficients.  
Part two of the questionnaire is a Visual Analogue Scale (VAS) where 
participants are asked place a point on a line of 0-100 where they think they are 
on the line, with 0 representing the worst imaginable health state and 100 
representing the best imaginable health state (46).   
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2.3.3 Brief Illness Perception Questionnaire (BIPQ) 
The Brief Illness Perception Questionnaire (BIPQ) was developed as a 
shortened version of the Illness Perception Questionnaire (IPQ). Composed of 9 
items, it aims to assess a number of cognitive and emotional representations of 
illness. Eight items assess perceived illness threat across eight areas related to 
their illness: consequences, timeline, personal control, treatment control, 
identity, concern, understanding and emotional response. The final item is a 
free-text item where subjects report their perceived illness cause. 
The 9 questions are: 
• How much does your illness affect your life? 
• How long do you think your illness will continue? 
• How much control do you feel you have over your illness? 
• How much do you think your treatment can help your illness? 
• How much do you experience symptoms from your illness? 
• How concerned are you about your illness? 
• How well do you feel you understand your illness? 
• How much does you illness affect you emotionally? (e.g. does it make 
you angry, scared, upset or depressed) 
• Please list in rank-order the three most important factors that you believe 
caused your illness. The most important causes for me:- 
The first 8 items of the BIPQ can be used to create an overall sum score of 
perceived illness threat by reversing the negatively worded items (74,75). 
2.3.4 Satisfaction with Life Scale (SWLS) 
Diener’s Satisfaction with Life Scale (SWLS) is a measure developed to assess 
global satisfaction with life. Life satisfaction is defined as a “global assessment 
of a person’s quality of life according to his/her chosen criteria”.  
The scale is composed of 5 items on a 7 point Likert scale form Strongly Agree 
to Strongly Disagree. The 5 items are: 
• In most ways my life is close to ideal 
• The conditions of my life are excellent 
• I am satisfied with my life 
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• So far I have gotten the important things I want in life 
• If I could live my life over, I would change almost nothing. 
The five items are all positive worded so a sum score of life satisfaction can be 
produced by adding scores together. The possible range of scores is therefore 
5 to 35, with 20 representing the scales neutral point (60,76).  
Sum scores can be interpreted as: 
• 5 to 9 – Extremely dissatisfied with life 
• 15 to 19 – Slightly dissatisfied with life 
• 20 to 24 – Neutral point 
• 21 to 25 – Slightly satisfied with life 
• 31 to 35 – Extremely satisfied with life 
2.3.5 Rosenberg Self-Esteem Scale (RSES) 
The Rosenberg Self-Esteem Scale is composed of 10 items; 5 positive 
statements and 5 negative statements. Originally designed as a Guttmann 
Scale with complex scoring, we instead used a sum score, reversing the 
negatively worded items. This is a commonly used approach to scoring (62). 
The 10 items of the scale are: 
• I feel that I am a person of worth, at least on an equal plane with others. 
• I feel that I have a number of good qualities 
• All in all, I am inclined to think I am a failure. 
• I am able to do things as well as most other people. 
• I feel I do not have much to be proud of. 
• I take a positive attitude toward myself. 
• On the whole, I am satisfied with myself. 
• I wish I could have more respect for myself. 
• I certainly feel useless at times. 
• At times I think I am no good at all. 
Each item is rated from Strongly Agree to Strongly Disagree on a 4-point scale 
(0-3).  
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3.1 Abstract  
Aims: Diet and exercise are the cornerstone of management of Type 2 DM but 
20-50% of people are non-adherent, possibly due to a reduction in wellbeing. 
The Early ACTID trial randomised patients to diet, diet and activity, or usual 
care in a 5:5:2 ratio. Patients in both intervention arms experienced improved 
glycaemia. We aim to assess the effects on patient-reported measures 
recorded, a secondary outcome of the trial. 
Methods:  Treatment satisfaction, quality of life, and wellbeing were assessed 
using five questionnaires: Diabetes Treatment Satisfaction Questionnaire 
(DTSQ)(n=512), EQ-5D(n=521), Brief Illness Perception Questionnaire(n=503), 
Rosenberg self-esteem scale(n=501) and Satisfaction with Life Scale(n=523). 
Analysis was performed on participants with complete data at baseline and 12 
months for each questionnaire. T-tests compared mean change from baseline 
score between study arms. 
Results: Baseline characteristics were similar; 64% vs 66% vs 68% male, 
median age 60.1 vs 60.4 vs 60.9 years, median days since diagnosis 184 vs 
187 vs 190, mean HbA1c 48.4 vs 48.9 vs 50.3 mmol/mol, mean BMI 32 vs 31 
vs 31 kg/m2. 
At 12 months, there was a marked improvement in DTSQ Satisfaction in those 
receiving a diet or diet and activity intervention compared to usual care (2.8 vs 
0.5, p=0.0008 and 2.5 vs 0.5, p=0.001) There were no differences between 
arms in quality of life or wellbeing. 
Conclusions: Diet and diet plus activity interventions in newly-diagnosed Type 
2 DM improve treatment satisfaction with no adverse effect on quality of life or 
wellbeing. The addition of exercise to a diet program did not affect treatment 
satisfaction, quality of life or wellbeing. 
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3.2 Background 
Dietary and physical activity advice form the backbone of the treatment of Type 
2 DM. Both the National Institute for Health and Care Excellence (NICE) and 
the American Diabetes Association (ADA) advise weight loss through lifestyle 
changes as an essential part of the management of Type 2 DM (77,78). Better 
food choices, portion control and eating patterns, alongside increased physical 
activity and reduced sedentary time comes with numerous benefits. These 
include improved glycaemic control and improved cardiovascular risk factors. 
This is seen both with diet and exercise prescription and behavioural 
interventions (17,19,79).  
The effects of these interventions on treatment satisfaction and quality of life are 
not fully understood, particularly early on in the disease when these 
interventions are most likely to be offered. Both the American Diabetes 
Prevention Program (DPP) (38) and the British DESMOND diabetes education 
and self-management programme (41) have looked at the effect of lifestyle 
interventions on quality of life in people newly diagnosed with Type 2 DM. In 
DPP, participants in the intensive lifestyle intervention arm (ILS) experienced a 
greater decline in physical function, health index and social functioning 
compared to both the metformin-treated and placebo-treated arms. In contrast, 
participants in the DESMOND study received a comprehensive diabetes self-
management and education programme including lifestyle advice, and 
experienced a very modest decline in quality of life, similar to that seen in the 
control group.  
Adherence to lifestyle interventions is a major issue with the Time2DoMore 
survey revealing adherence to dietary advice was 51% and adherence to 
exercise advice was just 40% (23). In a systematic review of barriers to exercise 
in people with Type 2 DM, dislike of exercise, sweating and physical discomfort 
from exercise were commonly cited as barriers (25). Similarly, in a survey of 
people with Type 2 DM in the USA, sticking to a diet was seen as a greater 
burden than taking oral glucose lowering agents (24).  Both of these findings 
suggest that having to adhere to a healthy diet and exercise regularly may 
reduce wellbeing in patients with Type 2 DM as was seen in the DPP. 
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This research aims to assess the potential impact of behavioural lifestyle 
interventions on treatment satisfaction, wellbeing, and quality of life. The Early 
ACTivity In Diabetes (Early ACTID) trial (72)  took place in the South West of 
England and aimed to assess whether physical activity advice given alongside 
dietary advice conferred significant additional benefits for people with newly 
diagnosed Type 2 DM. We believe patient reported measures recorded during 
this trial will provide strong evidence of the effects of these lifestyle changes on 
people with newly diagnosed Type 2 DM, and may identify associations that can 
be useful in predicting poor adherence and/or response to lifestyle 
interventions. Early ACTID had excellent retention of trial participants, achieved 
improvements in glycaemia in line with previous studies, and objectively 
measured activity levels and diet (80,81).  
 
  
63 
 
3.3 Participants and Methods 
3.3.1 The Early ACTID Study 
Early ACTID was a multicentre, parallel-group randomised controlled trial of 
lifestyle interventions which took place across five sites in South West England. 
The study was approved by the Bath Research Ethics Committee (05/Q2001/5), 
and all participants provided written informed consent. Participants were 
recruited through primary care with an original target sample size of 750, this 
was later reduced to 546 due to high retention and slower than anticipated 
recruitment.   
The trial has previously been described (72), but in brief 593 adults diagnosed 
with Type 2 DM were recruited through primary care between December 2005 
and September 2008.  Eligible participants had been diagnosed within the 
previous 5–8 months and were older than 30 years at diagnosis. Exclusion 
criteria were age older than 80 years, HbA1c concentration greater than 10% 
(85.8 mmol/mol), blood pressure higher than 180/100 mm Hg, LDL cholesterol 
concentration higher than 4 mmol/L, body-mass index (BMI) lower than 25 
kg/m2, weight greater than 180 kg, use of weight-loss drugs, taking a 
sulphonylurea at the maximum dose, unstable angina, a myocardial infarction 
within the previous 3 months, inability to increase physical activity, and 
pregnancy or planning to become pregnant.  
Participants were randomised, using a computer-generated allocation, in a 2:5:5 
ratio to usual care, an intensive dietary intervention, or an intensive dietary and 
physical activity intervention. Randomisation was stratified by centre and 
minimised by age, sex, fitness, route into study and blood pressure. Allocation 
was performed by the trial coordinator and concealed until after Visit 4 when 
dietitians phoned the trial coordinator and received the allocation code. Doctors 
were blinded to allocation but due to the nature of intervention nurses, dietitians 
and participants were aware of allocation. Participants in the usual care arm 
received lifestyle advice at a baseline dietitian visit, and were subsequently 
followed up by a doctor blinded to treatment allocation at 6 and 12 months. 
Participants in the intensive dietary intervention arm received usual care and an 
additional fifteen 20 minute sessions with a nurse or dietitian. The dietary 
intervention was not prescriptive and targeted weight loss of 5-10% through 
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daily calorie reduction of 500kcal and personalised goal setting. In addition to 
usual care and the dietary intervention, participants in the intensive dietary and 
physical activity group received pedometers (Digi-Walker CW200; Yamax, 
Yamasa Tokei Keiki Co., Ltd., Tokyo, Japan), motivational literature, and an 
activity diary. In addition to their existing levels of activity, they were asked to 
perform 30 minutes of brisk walking at least 5 days a week. Activity levels and 
goals were discussed during the same session as the dietary advice in order to 
keep contact time the same across both interventions.  
The effects of the Early ACTID interventions on glycaemia and a number of 
other outcomes have been previously reported (72). This analysis aims to 
assess the impact of the interventions on quality of life, wellbeing and 
satisfaction with treatment. Patient reported measures were recorded on paper 
copies given to participants at the 0, 6 and 12 month visits. Treatment 
satisfaction, quality of life, illness perception and wellbeing were assessed using 
five validated questionnaires. 
3.3.2 Treatment Satisfaction 
Diabetes-specific treatment satisfaction was assessed using the Diabetes 
Treatment Satisfaction Questionnaire (DTSQ) (63). It is a disease-specific 
treatment assessment tool recommended by the World Health Organisation 
(WHO) and International Diabetes Federation (IDF).  A satisfaction score is 
calculated from six of the questions. Questions are rated on a 7-point Likert 
scale (0-6, from dissatisfied to satisfied). The remaining two questions measure 
perceived frequency of hyper-/hypo- glycaemia and are not included in this 
analysis. 
3.3.3 Quality of Life and Illness Perception 
Health status was assessed using the Euroqol – 5 Dimensions 3 Level (EQ-5D) 
and Brief Illness Perception Questionnaire (BIPQ). The EQ-5D is a generic 
measure of quality of life recommended by the National Institute of Health and 
Care Excellence (NICE) (82). It is composed of 2 parts. Part one is made up of 
5 items scored on 3 levels to produce a Health Index according to the 
population norms. Part two is a Visual Analogue Scale (VAS) where participants 
rate their overall health from 0-100. Each part is assessed independently. 
Illness Perception was assessed using the Brief Illness Perception 
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Questionnaire (BIPQ). BIPQ is an abbreviated version of the Illness Perception 
Questionnaire (IPQ) (83).  It is made up of 8 items on 11-point scales from 0-10 
and a free text item on perceived cause of illness. A sum score of perceived 
illness threat can be created from the 8 scaled items after reversing scores for 
the negatively worded items. 
3.3.4 Wellbeing 
Wellbeing was assessed using Diener’s Satisfaction with Life Scale (SWLS) 
and Rosenberg’s Self-esteem Scale. The Satisfaction with Life Scale is 
composed of 5 items and assesses an individual’s subjective wellbeing 
(59).Each item is rated on a 1-7 scale, higher scores representing increased 
satisfaction. It is the preferred assessment tool of subjective wellbeing as it has 
excellent temporal reliability, internal consistency and good convergence with 
other measures. Self-esteem was assessed using the Rosenberg Self Esteem 
Scale (RSES) (84–86). It is a 10-item questionnaire with each item rated from 
Strongly Disagree to Strongly Agree on a 4-point scale. Originally a Guttman 
Scale, we like many others have opted to score each item between 0-3, 
reversing the scores of negatively worded items. The sum of all 10 items 
provides an overall score of self-esteem.  
3.3.5 Statistical Analysis 
Analysis was performed using Stata Statistical Software: Release 14 
(StataCorp, TX, USA). Parametric data is given as mean and standard deviation 
(SD) and non-parametric data as median and interquartile range (IQR). Where 
participants had provided multiple responses to a question, mean question 
scores were used and retained in the analysis. As change scores were normally 
distributed, between groups comparisons were performed using unpaired t-tests 
of change in score between baseline and 12 months. To allow for testing of all 
comparisons across the 3 arms, Bonferroni correction for multiple testing meant 
statistical significance was achieved at p<0.017. Associations were assessed 
using Pearson correlation coefficients. Given the minimum sample size used for 
comparisons in analysis is 80 vs 206, this would give us 80% power to detect a 
difference of 0.37 SD in our measurements.  Therefore, in this study we will be 
well powered to detect clinically relevant effect sizes which equate to ±2.0 for 
DTSQ, ±0.07 for EQ-5D Index, ±6.0 for EQ-5D VAS, ±3.1 for BIPQ, ±0.9 for 
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RSES, and ±2.5 for SWLS, using the baseline questionnaire scores as a 
reference.  
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3.4 Results 
Of the 579 participants that completed the trial, 545 completed at least one 
questionnaire in full at baseline and twelve months (range of n for analysis = 
501-523) (Figure 1). Follow-up was completed in September 2009.  The 
characteristics of participants included in this analysis are given in Table 1 and 
are similar to those of participants at randomisation.  At baseline there was no 
difference between the three arms in terms of age, sex ratio, BMI, HbA1c, time 
from diagnosis and oral hypoglycaemic agents. Table 2 summarises the results 
for all questionnaires. It includes baseline scores, endpoint scores and change 
scores. 
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Table 1 - Cohort Characteristics 
Baseline Characteristics 
Given as mean(sd) unless 
otherwise stated 
Usual Care 
(n=85) 
Diet (n=234) Diet and Physical 
Activity (n=226) 
Male Sex 54(64%) 154(66%) 154(68%) 
Age in years 60.1(10.7) 60.4(10.0) 60.9(9.0) 
Caucasian 83(98%) 227(97%) 214(95%) 
Married or with long-term 
partner 
64(75%) 178(76%) 180(80%) 
Median (IQR) days since 
diagnosis  
184(149-223) 187(153-225) 190(149-233) 
BMI 32(5.0) 31(5.8) 31(5.1) 
HbA1c (%) 6.6(0.9) 6.6(0.9) 6.8(1.0) 
HbA1c (mmol/mol) 48.4(9.7) 48.9(10.0) 50.3(11.4) 
Minutes of moderate to 
vigorous activity per day 
26.9(21.0) 25.8(19.6) 23.3(18.3) 
Oral hypoglycaemic agents 
• Metformin 
• Sulphonylurea 
• Thiazolidinedione 
• Total 
 
25(29%) 
6(7%) 
2(2%) 
28(33%) 
 
83(35%) 
19(8%) 
1(<1%) 
91(39%) 
 
77(34%) 
20(9%) 
3(1%) 
87(38%) 
Antihypertensive agent 50(59%) 159(68%) 129(57%) 
Lipid-lowering drugs 55(65%) 152(65%) 141(62%) 
Antiobesity agents 0 0 0 
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Figure 1 - CONSORT diagram 
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Table 2 – Summary of Questionnaire Results. Baseline and 12 month results 
are given as median (IQR). 12 month change scores are given as mean (SD). 
T-tests were used to compare means and Mann-Whitney U Tests to compare 
medians. Statistical significance was achieved at p<0.017 after Bonferroni 
correction, *denotes statistical significance. 
  Trial Arm P values 
  Usual Care Diet Diet and 
Physical 
Activity 
Usual Care 
vs Diet 
Usual Care 
vs Diet and 
Physical 
Activity 
Diet vs Diet 
and 
Physical 
Activity 
Diabetes Treatment Satisfaction Questionnaire (DTSQ) (maximum score 36) 
N 83 216 213 
   
Baseline 32(26-35) 31(27-34) 31(27-34) 0.3 0.6 0.5 
12 months 31(28-35) 33.5(30-35) 34(31-36) 0.01* 0.007* 0.6 
12 month Change  0.53(5.23) 2.82(5.24) 2.46(4.36) 0.0008* 0.001* 0.4 
EQ-5D Health Index (maximum score 1) 
N 81 223 217 
   
Baseline 0.80(0.73-1) 0.80(0.73-1) 0.88(0.73-1) 0.6 0.05 0.03 
12 months 0.80(0.69-1) 0.85(0.73-1)  0.85(
0.73-1) 
0.02 0.005* 0.5 
12 month Change  -0.05(0.23) 0.00(0.15) -0.02(0.15) 0.03 0.2 0.2 
EQ-5D Visual Analogue Scale (EQ-5D VAS) (maximum score 100) 
N 82 222 215 
   
Baseline 75(62-85) 75(65-85) 79(65-85) 0.7 0.3 0.4 
12 months 75(66-80) 80(70-85) 80(70-90) 0.03 0.01* 0.5 
12 month Change  -0.62(16.3) 2.87(14.6) 2.40(16.8) 0.07 0.2 0.8 
Brief Illness Perception Questionnaire (BIPQ) (maximum score 80) 
N 80 217 206 
   
Baseline 44(39-51.5) 46(41-52) 44.5(40-49) 0.2 0.9 0.07 
12 months 45(38-50.5) 45(41-51) 45(41-50) 0.1 0.2 0.5 
12 month Change  -0.49(6.30) 0.14(6.57) 0.75(6.82) 0.5 0.2 0.3 
Rosenberg’s Scale of Self-Esteem (RSES) (maximum score 30) 
N 80 214 207    
Baseline 20(18-22) 20(18-22) 20(18-22) 0.7 0.5 0.8 
12 months 20(18-22) 21(18-22) 20(18-23) 0.2 0.1 0.8 
12 month Change  -0.20(2.13) 0.17(2.08) 0.17(2.73) 0.2 0.3 0.9 
Satisfaction with life scale (SWLS) (maximum score 35) 
N 78 226 219    
Baseline 23(16-29) 25(20-29) 26(20-30) 0.06 0.03 0.7 
12 months 22(18-29) 27(20-30) 26(20-30) 0.02 0.001* 0.8 
12 month Change  0.37(6.15) 0.40(4.81) 0.50(4.69) 1.0 0.8 0.8 
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3.4.1 Treatment Satisfaction 
Intensive dietary intervention with and without physical activity advice improved 
treatment satisfaction compared to usual care (Fig. 2). Participants receiving the 
intensive dietary intervention had a mean (SD) improvement in satisfaction 
score of 2.8 (5.2) compared to usual care 0.5 (5.2) (p=0.0008). In addition, 
those who received intensive dietary and physical activity advice improved by 
2.5 (4.4) compared to the 0.5 (5.2) improvement in usual care (p=0.001). 
However, the addition of physical activity advice did not provide a greater 
increase in treatment satisfaction than when dietary advice was given alone 
(p=0.4). This was despite high baseline treatment satisfaction across all 
treatment arms with median (IQR) scores of 32 (26-35), 31 (27-34) and 31 (27-
34). At 6 months, treatment satisfaction improved in all arms, with mean (SD) 
change of; 1.0 (4.5) in the usual Care arm, 2.6 (5.8) in the diet arm, and 1.78 
(4.7) in the diet and activity arm. There was no statistically significant difference 
between arms (p>0.03).  
The largest improvements were seen in the understanding and satisfaction 
items (Fig. 3). The understanding component of DTSQ asks patients “How 
satisfied are you with your understanding of your diabetes?” Participants in the 
intensive dietary intervention and intensive dietary and physical activity 
intervention arms both had a mean improvement of 0.6 in this component. 
Participants receiving usual care improved by just 0.2. In addition, the 
satisfaction component of DTSQ asks patients “How satisfied are you with your 
current treatment?” and both intervention arms had mean improvements of 0.6 
and 0.5 in this component, compared to a modest improvement of 0.1 in the 
usual care arm.  
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Figure 2 – Mean (95% CI) change from baseline Diabetes Treatment 
Satisfaction Questionnaire (DTSQ) Satisfaction Score 
 
Figure 3 – Mean (95% CI) change from baseline score at 12 months in 
Diabetes Treatment Satisfaction Questionnaire (DTSQ) Components of 
Satisfaction Score 
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3.4.2 Quality of Life, Illness Perception, and Wellbeing 
Quality of life, illness perception and wellbeing were unchanged after 12 months 
across all trial arms. There were no between arm differences in mean change in 
any of these measures. Non parametric comparison of raw scores at 12 months 
showed a small statistically significant difference in 12 month median EQ-5D 
Index between both intervention arms and control (Usual Care 0.80 vs Diet 
0.85, p=0.015; Usual Care 0.80 vs Diet and Activity 0.85, p=0.005).  However, 
there was no difference in mean change from baseline score (p=0.03 and p=0.2 
respectively), There was also a small statistically significant difference between 
the usual care and the diet and activity arms of the trial in 12 month median EQ-
5D VAS (75 vs 80, p=0.01) and SWLS (22 vs 26, p=0.001) but again no 
difference in mean change from baseline (-0.62 vs 2.40, p=0.2; 0.37 vs 0.50, 
p=0.8). 
Baseline life satisfaction, self-esteem and quality of life were not predictive of 
response to treatment in terms of weight or glycaemia. Pearson correlation R 
values were all ≤0.1 with no correlations reaching statistical significance.  
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3.5 Discussion 
In this study, we have shown that motivational interview-based behavioural diet 
and diet plus physical activity interventions improved treatment satisfaction in 
early Type 2 DM. Quality of life, illness perception and wellbeing were all stable 
over the course of the trial across all arms and no different between arms. None 
of the patient reported measures recorded in this study were associated with a 
change in weight or glycaemia in the intervention or control arms. These 
findings suggest that an individual’s quality of life and/or wellbeing is not altered 
by, or has an effect on, the impact of a diet or  diet plus physical activity 
intervention. This suggests that poor adherence to lifestyle programmes is not 
due to them having adverse effects on quality of life and/or wellbeing. It also 
underlines that these programmes are effective for patients who have low 
psychological wellbeing or high levels of stress about their disease.  
We were not surprised to see an improvement in diabetes treatment satisfaction 
in the diet and diet and activity arms. Improvement in treatment satisfaction was 
seen in the intervention arm of the Diabetes X-PERT study in which patients 
with established Type 2 DM attended six 2 hour sessions of self -management 
education (67) Similar improvements have been seen in studies of long acting 
and rapid acting insulins, incretin-related agents, sodium-glucose 
cotransporter 2 (SGLT2) inhibitors, fixed-dose combination tablets and 
dipeptidyl peptidase-4 (DPP-4) inhibitors (65).The improved glycaemic control, 
weight loss, and reduced need for drug treatment seen in both intervention arms 
were probably the reasons for the improvement in Diabetes treatment satisfaction 
(72). The fact that the improvement in these factors was no different between the 
two intervention arms also probably explains why no difference in treatment 
satisfaction was seen between the intervention arms. 
Only two studies have assessed the impact of behavioural lifestyle interventions 
on wellbeing and quality of life in newly diagnosed Type 2 DM. The DPP found 
that in individuals who were diagnosed with Type 2 DM, those in the intense 
lifestyle intervention (ILS) arm had a greater fall in quality of life than those in 
the metformin or control arm over up to six years of follow up (38). Whether this 
was due to them having experienced more intense disappointment when, in 
spite of actually losing weight, they still developed diabetes or due to the fact 
that the intervention was very intense, prescriptive and involved making 
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significant changes in their diet and patterns of physical activity is not known. In 
contrast, in the DESMOND study, participants who received the intervention 
experienced a very modest decline in quality of life, similar to that seen in the 
control group (41). The intervention used in the DESMOND study was similar to 
that used in ACTID, being a non-supervised intervention that emphasised 
patient understanding and self-management and had total contact time of 6 
hours. 
The diet and diet and activity interventions only produced a - 2.41kg (95% CI -
3.49 to -1.32; P<0.0001) and - 2.25kg (95% CI -3.35 to -1.16; P<0.0001) weight 
loss compared to the usual care arm which might not have been enough to 
have an effect on wellbeing or quality of life. A review of the relationship 
between weight loss and health related quality of life suggested that 
improvements were only seen if weight loss was significant (87). In the DiRECT 
study, a randomised control trial of an intense weight management programme 
in patients with established Type 2 DM, a weight loss of -8.8kg (95% CI -10.3 to 
-7.3; p<0.0001) was seen compared to the usual care group (22). In this study 
quality of life, as measured by the EQ5D VAS, improved by 6.4 points (95% CI 
2-5 to 10.3; p=0.012) in the weight management arm compared to the usual 
care arm.  
It was disappointing not to see a difference in wellbeing and quality of life 
between the diet and diet and activity arms.  It is difficult to know if increasing 
activity levels more than the 9.1 (95% CI 4.45 to 13.75; p=0.036) minutes per 
day that was achieved in the diet and activity arm would have resulted in an 
improvement in wellbeing and/or quality of life. DESMOND and the DPP did not 
objectively measure activity and the small exercise focused studies found mixed 
effects on wellbeing and quality of life and could not establish a threshold of 
effect (44). Similarly, whether adding an anaerobic component to the diet and 
activity arm, (the exercise focus was on increasing aerobic activity) would have 
resulted in an improvement in wellbeing and/or quality of life is not known.  The 
small studies that have compared the effect of different forms of exercise on 
quality of life and wellbeing have not been able to determine whether one type 
or combinations of types of exercise are better (44).  
Our study had several strengths. First, it included well-validated measures of 
treatment satisfaction, quality of life, and illness perception. Second, the three-
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arm design allowed for direct comparison between a behavioural dietary 
intervention given alone and when delivered in combination with a behavioural 
physical activity intervention. Third, excellent retention meant 545 of 593 (92%) 
participants at randomisation completed at least one questionnaire in full at both 
baseline and 12 months, with at least 501 results available for each 
questionnaire analysis. This provides us with confidence our study was 
adequately powered to detect clinically significant changes in each measure. In 
addition, Early ACTID objectively measured diet and activity levels which 
allowed us to ensure that participants receiving the intervention had indeed 
changed their diet and activity levels.  
There are also limitations worth noting. First, the study participants were not 
ethnically diverse with 96% Caucasian. A more diverse ethnic group might have 
resulted in different findings. Second, the unblinded nature of the trial (i.e., to 
participants and study staff) may have influenced participant expectations about 
the efficacy of the intervention to which they were assigned. Third, using the 
Diabetes Treatment Satisfaction Questionnaire change version with the original 
Treatment Satisfaction Questionnaire may have enabled us to explore in more 
detail the improvement that patients saw with the intervention arms (73,88). 
Finally, the absolute improvement in HbA1c and weight loss were modest in 
both intervention arms. Had there been greater improvement in these, we might 
have seen changes in quality of life and wellbeing in the intervention arms. 
In summary, we have found that motivational interview-based behavioural diet 
and diet plus physical activity interventions improved treatment satisfaction in 
early Type 2 DM without adversely impacting wellbeing and quality of life. In 
addition, quality of life and wellbeing were not associated with response to 
these interventions. However, what we aren’t able to say from our results is 
whether these interventions are able to prevent or delay decline in quality of life. 
Evidence from the usual care arm suggests that quality of life is stable in newly 
diagnosed Type 2 DM, but this was in a trial environment where participants 
received “enhanced” usual care. Future work on the impact of lifestyle changes 
in newly diagnosed Type 2 DM should consider looking at changes in quality of 
life in prospective studies instead of interventional trials. To aid this work further, 
standardisation of patient reported measures used in future studies should be a 
priority as currently work in this area is made difficult by the large variation in 
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different measures used (89,90). This makes cross-comparison difficult and 
prevents meta-analysis of studies from which stronger conclusions can be 
drawn. 
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4.1 Abstract 
Background and aims: People living with Type 2 Diabetes (T2DM) report 
poorer quality of life than those without the disease. It is not clear whether there 
is a fall in quality of life due to being diagnosed with T2DM or whether this falls 
over time due to living with the disease. Some studies have shown quality of life 
declines initially at diagnosis but then returns to its previous level but the 
DPPOS found it declined over 6 years of follow up. In this study we aimed to 
assess quality of life, treatment satisfaction and wellbeing in a cohort with 
recently diagnosed T2DM in the United Kingdom over 6 years. 
Materials and methods: The cohort we used were participants enrolled in the 
Early ACTID Trial. Participants with newly-diagnosed Type 2 diabetes were 
randomised to a 1 year diet intervention, a 1 year diet and activity intervention, 
or usual care in a 5:5:2 ratio. At the end of the year participants’ care was 
returned to their general practitioner and they were seen annually for a further 5 
years. Patient-reported measures (PRMs) were recorded at 0, 6, 12, 24, 36, 48, 
60, 72 months; these were EQ-5D, BIPQ, DTSQ, RSES, and SWLS. Analysis 
was performed using mixed effects linear regression to allow for clustering of 
results within individuals. 
Results: Baseline cohort characteristics were: 64% male, median age 60 years, 
median time since diagnosis 189 days, mean Hba1c 49.8 mmol/mol, mean BMI 
31.6. At baseline 589 of 593 (99%) participants completed at least one 
questionnaire in full. This fell across the study with 551 (93%) at year 1 and 290 
(49%) at year 6. Health status declined gradually over six years irrespective of 
trial arm. Those whose diabetes progressed during the trial had poorer quality 
of life than those who progressed during follow up (-0.5, 95% CI 0.01, 0.09; 
p=0.009). Perceived illness threat fell across the six years (-0.2, p=0.005), this 
was lowest in participants whose diabetes did not progress but was not 
statistically significant (-1.3, p=0.2). 
Conclusion: Quality of life of declines gradually over the first six years of Type 
2 diabetes. This decline appears to be associated with progression of diabetes 
though further clarification is required. Participants’ perception of illness threat 
decreased slowly, suggesting they came to terms with the impact of their 
illness, particularly in those whose disease did not progress. Wellbeing was 
stable although depression was not assessed. 
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4.2 Background 
Quality of life is a hugely important outcome in healthcare. Although various 
definitions exist it can described well as “a multi-faceted construct that 
encompasses the individual’s behavioural and cognitive capacities, emotional 
well-being and abilities requiring the performance of domestic, vocational and 
social roles” (91). Its importance in Type 2 Diabetes (Type 2 DM) is increasingly 
highlighted (92). 
Those with Type 2 DM report poorer quality of life than those without the 
disease (30,93) . This quality of life falls further if the person has macrovascular 
or microvascular complications, depression, or is taking more than 7 tablets 
(39,40).  Level of long term glucose control (HbA1c) and which treatment is 
used to treat diabetes does not affect quality of life (5,6).  
It is less clear what changes in quality of life occur in newly diagnosed diabetes 
prior to the development of complications. Early research suggested a dip 
around the time of diagnosis that quickly returned to its previous level (35–
37,94). The American Diabetes Prevention Program Outcomes Study (DPPOS) 
followed quality of life in those people in whom diabetes was diagnosed despite 
the interventions (38). Quality of life declined over six years irrespective of trial 
arm. However, it is not known whether this is the same in people who were not 
made aware of their risk and developed diabetes despite efforts to prevent it. 
Our cohort is composed of the participants of the Early ACTivity In Diabetes 
(Early ACTID) randomised control trial and its follow up study ACTID Plus. Early 
ACTID aimed to determine whether the addition of physical activity advice to 
dietary advice conferred an additional benefit above dietary advice alone in 
newly diagnosed Type 2 DM. After completion of the interventions at 1 year, 
there was improved treatment satisfaction in the intervention groups but there 
no change in health status, life satisfaction, self-esteem and illness perception 
and no difference between arms (Chapter 3). Following this, participants we 
were re-consented to the follow up study ACTID Plus which followed 
participants annually for a further 5 years. In this study we use patient reported 
outcome measures recorded during the trial, and at each follow up visit, to 
analyse changes in these measures over time. This study also aims to identify 
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whether progression of diabetes was associated with changes in these 
measures.    
4.3 Participants and Methods 
4.3.1 Cohort & Measures Used 
Our cohort is composed of the participants of the Early ACTID randomised 
control trial and its follow up study ACTID Plus. Funding for ACTID plus was 
delayed which meant that some people had gone past their 1st year of follow up 
before the follow up started. For this reason there is more missing data at the 
first year of follow up (2 years post-randomisation). This is described in full in 
Chapter 2.  
The measures we used are also described in Chapter 2. 
Progression of diabetes was a binary survival outcome defined by an increase 
in HbA1c of >5 mmol/mol or the addition of ≥ 1 diabetes medication(s). 
4.3.2 Statistical Analysis 
All analysis was performed using Stata Statistical Software: Release 14 
(StataCorp, TX, USA). Longitudinal analysis of each patient-reported outcome 
measure was performed using mixed effects linear regression modelling. 
Models were adjusted for Early ACTID trial arm, age, sex and BMI. Analysis of 
the association between each patient-reported outcome measure and diabetes 
progression was also performed using mixed effects linear regression. For this 
analysis, participants were categorised according to whether their disease; 
progressed during the trial, progressed during follow up, or did not progress. 
Those with missing progression data were excluded from this analysis.  
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4.4 Results 
4.4.1 Baseline Characteristics 
Of 593 enrolled participants, 589 had complete data for at least one patient 
reported outcome measure at baseline. The number of individuals who 
completed at least one measure in full at 6, 12, 24, 36, 48, 60, and 72 months 
was 542, 551, 193, 298, 316, 286, and 290. Baseline cohort characteristics for 
all individuals included in the analysis, those with complete for at least one 
measure at years, and those without data at 6 years are given in Table 1. There 
were small differences in age, sex and BMI between individuals with 6 year data 
and those without, but otherwise baseline clinical characteristics were similar. 
Importantly, baseline patient reported outcome measures were similar between 
these two groups. The main results of this study are displayed in Figure 1. 
Results split by trial arm are shown in Table 2. Results with participants 
categorised by time of diabetes progression are displayed in Figure 2. Figure 3 
displays linear trends seen in EQ-5D Index. 
4.4.2 Quality of Life  
There was a very gradual decline in EQ-5D Index (-0.01 per year, p<0.001) and 
at six years this represented a clinically significant reduction in health status 
with a reduction of -0.06 between baseline and 6 years (p<0.001). This did not 
differ between treatment arms.  
There was very modest decline EQ-5D VAS, with an annual decline of -0.4 
(p=0.002) and change of -2.1 from baseline to 6 years (p=0.03). There were no 
significant differences between arms.  
Categorising participants by their time of progression and modelling their 
trajectories at each time point suggested those who progressed within the trial 
had poorer quality of life than the rest of the cohort (Figure 2). The rest of the 
cohort was divided into those whose diabetes progressed during follow-up, and 
those who did not progress.  
To investigate this further we modelled time as a continuous variable (Figure 3). 
We found scores in those who progressed during the trial were significantly 
lower than those who progressed during follow up (-0.5, 95% CI 0.01, 0.09, 
p=0.009), but not statistically significantly different to those who did not 
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progress (-0.4, 95% CI -0.01, 0.09; p=0.09).The annual rate of decline (-0.01, 
95% CI -0.02, 0.00; p=0.007) did not differ between the categories (p=0.7 & 
0.9).   
4.4.3 Illness Perception 
There was a modest decline in perceived illness threat measured by BIPQ sum 
score. The annual decline was -0.2 (p=0.005) with a reduction of -0.9 from 
baseline to six years. There were no significant differences between trial arms.  
Those whose diabetes did not progress over the six years of follow up had a 
greater reduction in perceived illness threat compared to those in whom 
diabetes progression was seen (Figure 3). However, these differences were not 
statistically significant. Compared to those who progressed during the trial this 
difference was 1.3 (95% CI -0.6, 3.3; p=0.2) and compared those who 
progressed during follow up was 1.3 (95% CI -0.5, 3.1; p=0.2). 
4.4.5 Global Life Satisfaction and Self Esteem 
Self-esteem was stable over the course of the study (annual trend +0.05, 
p=0.004). This resulted in a difference of just 0.3 between baseline and six 
years. There was no statistically significant difference between trial arms. 
Global life satisfaction remained remarkably stable over the course of the study 
with no significant annual trend (p=0.4) or difference between baseline and six 
years (p=1). 
Self-esteem was higher in those whose diabetes did not progress compared to 
those who progressed during the trial but the effect size was small (0.65, 95% 
CI 0.0, 1.3; p=0.04). Life satisfaction was significantly lower in those who 
progressed during the trial than those who did not progress but this was likely 
due to a large baseline difference (-2.7, 95% CI -4.3, 1.0; p=0.002). 
4.4.6 Treatment Satisfaction 
Treatment satisfaction improved rapidly during the one year of Early ACTID with 
a mean modelled annual increase of 1.0 (p<0.001). However, after participants 
stopped receiving the interventions these values quickly returned to their 
original level (-0.4 annual trend, p<0.001). Both intervention arms improved 
significantly greater than those in the usual care between baseline and one year 
but there was no difference between arms from one year to six years. 
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Table 1 – Baseline cohort characteristics for individuals who completed 
questionnaires out to six years and those who did not.  
Baseline 
Characteristics 
Cohort with 
baseline data 
Cohort with 6 
year data 
Cohort without 
6 year data 
Proportion of trial 
cohort (%) 
589 (99%) 290 (49%) 303 (51%) 
Proportion 
allocated Usual 
care (%) 
99 (100%) 38 (38%) 61 (61%) 
Proportion 
allocated Diet (%) 
247 (99.5%) 123 (50%) 125 (50%) 
Proportion 
allocated Diet and 
activity (%) 
243 (99%) 129 (52%) 117 (48%) 
Proportion 
Caucasian (%) 
582 (96%) 281 (99%) 282 (93%) 
No. male (%) 379 (64%) 207 (71%) 174 (57.4%) 
Mean Age (sd) 59.9 (10.2) 61.0 (8.9) 59.0 (11.1) 
Mean BMI (sd) 31.6 (5.7) 30.9 (5.4)  32.4 (5.9) 
Mean baseline 
HbA1c % (sd) 
6.7 (1.0) 6.6 (0.9) 6.8 (1.0) 
Mean baseline 
HbA1c mmol/mol 
(sd) 
49.8 (11.0) 49.0 (10.3) 50.3 (11.4) 
Median days since 
diagnosis at 
baseline (iqr) 
189 (152-230) 187 (153-226) 190 (150-233) 
Mean daily 
minutes of MVPA 
(sd) 
24.8 (19.0) 25.3 (19.5) 24.1 (18.4) 
Median baseline 
EQ-5D Index 
(IQR) 
0.85 (0.73-1) 0.85 (0.73-1) 0.85 (0.73-1) 
Median baseline 
EQ-5D VAS (IQR) 
75 (65-85) 75.5 (65-85) 75.5 (65-85) 
Median baseline 
SWLS Score 
(IQR) 
25 (19-29) 26 (20-29) 24 (18-29) 
Median baseline 
RSES Score 
(IQR) 
20 (18-22) 20 (18-22) 20 (18-22) 
Median baseline 
BIPQ Score (IQR) 
46 (40-52) 46 (41-52) 45 (41-52) 
Median baseline 
DTSQ Score 
(IQR) 
31 (26-34) 32 (27-34) 30(26-34) 
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Table 2 – Model baseline-endpoint contrasts and annual trends split by trial arm 
 
Usual Care Diet Diet and 
Activity 
EQ-5D Health Index  (scores range from -0.594 to 1) 
Year 6 vs Baseline -0.06 (-0.1, 
0.00), p=0.04 
-0.06 (-0.1, -
0.03), p<0.001 
-0.05(-0.08, -
0.02), p=0.003 
Annual Trend -0.01(-0.02, -
0.01), p<0.001 
-0.01(-0.01, 
0.00), p<0.001 
-0.01(-0.01, 
0.00), p=0.001  
EQ-5D Visual Analogue Scale (scores range from 0 to 100) 
Year 6 vs Baseline -3.3(-8.6, -2.0), 
p=0.2 
-2.7(-5.7,0.3), 
p=0.08 
-1.2(-4.1,1.8), 
p=0.4 
Annual Trend -1.0(-1.7, -0.3), 
p=0.004 
-0.5(-0.9, 0.0), 
p=0.03 
-0.2(-0.6, 0.2), 
p=0.3 
Brief Illness Perception Questionnaire (scores range from 0 to 80) 
Year 6 vs Baseline -1.6(-3.9, 0.7), 
p=0.2 
-1.3(-2.6, 0.0), 
p=0.06 
-0.3(-1.6, 1.0), 
p=0.7 
Annual Trend -0.3(-0.6, 0.0), 
p=0.05 
-0.2(-0.3, 0.0), 
p=0.09 
-0.2(-0.3, 0.0), 
p=0.09 
Satisfaction with Life Scale (scores range from 5 to 35) 
Year 6 vs Baseline 0.8(-0.9,2.5), 
p=0.4 
0.7(-0.3, 1.6), 
p=0.2 
-0.3(-1.2, 0.7), 
p=0.5 
Annual Trend -0.2(-0.4, 0.1), 
p=0.2 
0.1(-0.1, 0.2), 
p=0.4 
-0.01( -0.1, 0.0), 
p=0.9 
Rosenberg Self-Esteem Scale (scores range from 0 to 30) 
Year 6 vs Baseline -0.1(-0.8, 0.6), 
p=0.7 
0.3(-0.1, 0.7), 
p=0.5 
0.6(0.2, 0.9), 
p=0.006 
Annual Trend -0.08(-0.2, 0.0), 
p=0.1 
0.05(0.0, 0.1), 
p=0.07 
0.1(-0.1, 0.1), 
p=0.9 
Diabetes Treatment Satisfaction Questionnaire (scores range from 0 to 
36) 
Year 6 vs Baseline 0.06 (-1.7, 1.8), 
p=0.9 
0.4 (-0.6, 1.4), 
p=0.4 
0.6 (-0.4, 1.6), 
p=0.2 
Annual Trend Year 
0-1 (trial) 
0.4 (-0.3, 1.1), 
p=0.3 
1.0 (0.5, 1.4), 
p<0.001 
1.2 (0.7, 1.7), 
p<0.001 
Annual trend Years 
1-6 (follow up) 
-0.5 (-0.7, -0.2), 
p<0.001 
-0.5 (-0.6, -0.3), 
p<0.001 
-0.3 (-0.5, -0.2), 
p<0.001 
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Figure 1 -   Longitudinal trends in questionnaire scores with time as discrete events; (A) Health Status measured by EQ-5D Index, (B) 
perception of health measured by EQ-5D VAS, (C) perceived illness threat measured by BIPQ, (D) life satisfaction measured by SWLS, 
(E) self-esteem measured by RSES, and (F) treatment satisfaction measured by DTSQ. 
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Figure 2 – Longitudinal trends in questionnaire score with time as discrete events, categorised by time of diabetes progression; (A) 
Health Status measured by EQ-5D Index, (B) perception of health measured by EQ-5D VAS, (C) perceived illness threat measured by 
BIPQ, (D) life satisfaction measured by SWLS, (E) self-esteem measured by RSES, and (F) treatment satisfaction measured by DTSQ. 
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Figure 3 – Longitudinal trends in questionnaire scores with time as continuous 
variable; (A) Health status measured by EQ-5D Index, and (B) perceived illness 
threat measured by BIPQ 
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4.5 Discussion 
In this study we found health status as measured by EQ-5D Index declined 
slowly over the six years following diagnosis and this represented a significant 
decline. Declines in EQ-5D VAS score and BIPQ sum score of illness threat 
were also seen but these were modest and did not reach a level considered 
clinically significant.  We also found people who had progression of their 
diabetes during the trial had lower quality of life than both those who progressed 
during follow up and those who did not progress. Those who did not have 
progression of their diabetes had lower perceived illness threat. These results 
are important as they suggest preventing progression of diabetes through early 
lifestyle interventions is vital to delaying or preventing the decline in quality of 
life seen over this period.  
The decline in health status that we saw in this study over the six years was in 
keeping with previous studies. Early studies suggested there was dip in quality 
of life at the time of diagnosis but this quickly returned to its previous level (35–
37). The American Diabetes Prevention Program Outcomes Study (DPPOS) 
presented a unique opportunity to assess the impact of diagnosis on quality of 
life (38). Participants who despite the interventions went on to develop diabetes 
were followed for up to 6 years following diagnosis. Quality of life was measured 
using the SF-36 generic measure of health related quality of life. Physical 
component summary scores fell in all trial arms in those with diabetes and 
mental component summary scores fell in the lifestyle intervention (ILS) arm. 
This fall could have been due to them feeling disheartened to have developed 
Type 2 DM despite their best efforts, as a result of the number of lifestyle 
changes that they were being asked to make or alternatively due to progression 
of their diabetes. Our results suggest this decline was a normal part of the 
progression of Type 2 DM over this period. 
The fact we saw a significant decline in EQ-5D Index but only a very modest 
decline in EQ-5D VAS is intriguing.  This is likely be due to the fact EQ-5D VAS 
incorporates individuals’ perception as well as functional status as it asks 
individuals to place on a line from 0-100 their perceived health state. This is not 
the case for EQ-5D Index which is restricted to five domains. The fact we also 
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saw a concurrent decline in perceived illness threat might explain why the EQ-
5D VAS did not fall as much as the EQ-5D.    
Our finding that perceived illness threat fell over time is in keeping with other 
studies in this area which have shown perceived illness threat is low in newly 
diagnosed diabetes, prior to the development of complications (41,95,96). 
Participants in the Early ACTID study, irrespective of the arm that they were 
allocated to, received enhanced care with the usual care arm being seen 11 
times across the year and those in the interventions arms 17 times.  This 
increased contact may have increased their understanding of their disease and 
this reduced how threatening they saw their disease. In the Diabetes Education 
and Self-Management for Ongoing and Newly Diagnosed (DESMOND) study, 
reduced illness threat was also seen as measured by the Revised Illness 
Perception Questionnaire (IPQ-R). They found illness understanding and 
personal control were higher in the intervention compared to the control group 
up to three years post-intervention. 
By categorising participants according to their time of diabetes progression, our 
results suggest those whose diabetes progressed during the trial had the 
poorest quality of life. Although this difference was only statistically significant 
when compared to those who progressed during the trial, likely due to the larger 
numbers in this group. This may have been due to participants’ disappointment 
at having not achieved better control through lifestyle changes, or may be the 
result of poorer self-efficacy, self-care and adherence to treatment. In contrast, 
those whose diabetes did not progress over the six years of follow up perceived 
their illness to be less threatening, than those whose diabetes progressed at 
any point during follow up. These results suggest preventing early progression 
of diabetes through lifestyle changes may prevent or delay the decline in quality 
of life normally seen in the first years following diagnosis of Type 2 DM. 
We were surprised to see no difference in quality of life or wellbeing between 
the treatment arms and the control group over time. The interventions as well as 
being designed to help people to improve their diet and increase their activity, 
also provided them with education about diabetes and skills to overcome 
barriers and prevent relapse. By doing this we hoped that participants would be 
able to maintain the changes that they had made to their lifestyles and hoped 
that this would lead to an improvement in wellbeing and quality of life. In the 
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DESMOND study there was also no difference in quality of life as measured by 
the WHOQOL-BREF between the intervention and control arm. However, in the 
DESMOND study illness understanding was improved in the intervention group, 
compared to usual care up to three years following the intervention (41). The 
education programme in the DESMOND study differed from the ACTID 
programme in that it was delivered in groups and used different psychological 
theories. In addition, those participants in the control arm in the ACTID study at 
12 months received all of the teaching material that had been used in the 
interventions arms. Any or all of these differences might explain why the 
DESMOND study was able to show an improvement between their treatment 
arm and control arm but our trial was not able to. 
Our results in treatment satisfaction highlight the importance of increased 
contact time and the effect of a trial environment on people’s satisfaction with 
the care they receive. The improvement in satisfaction that occurred in all arms 
over 1 year, which was significantly greater in the intervention arms, was lost as 
soon as participants left the trial. We believe this shows the beneficial impact 
taking part in a trial has on the clinical care of participants. 
To our knowledge, alongside DPPOS this study is the longest duration study of 
quality of life in people with newly diagnosed Type 2 DM and has number of 
strengths. Firstly, there was adequate retention of trial participants with almost 
half (49%) of participants with baseline data retained at six years. In addition, 
baseline scores in these measures were similar between those individuals lost 
at six years and those retained. Secondly, the measures we used all display 
good reliability and validity. Finally, with the only treatment satisfaction differing 
between arms and this effect being lost after completion of the trial, we were 
able to combine all participants into a single cohort to provide increased 
statistical power to detect changes in these measures.  
There are some important limitations to note. As Early ACTID recruited people 
in whom a diagnosis of Type 2 DM was made 3-8 months previously, we were 
unable to capture any changes that occur immediately at diagnosis. Secondly, 
the slight difference in baseline clinical characteristics in those retained and 
those lost at six years may have influenced our results. Thirdly, participants’ 
involvement in Early ACTID (the majority in intervention arms) may have had a 
lasting impact, particularly on quality of life and illness perception, as even 
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those in the control arm received an “enhanced” usual care. This may 
somewhat reduce the generalisability of our findings to the real world. In 
addition, in order to analyse our findings based on time of diabetes progression 
we were forced to categorise our cohort into groups. However, more complex 
joint modelling with diabetes progression as a survival outcome would better 
assess this association. Finally, disentangling changes in quality of life due to 
Type 2 DM and those that occur with ageing and the acquisition of comorbid 
diseases is not is possible from our study. The use of a diabetes-specific 
measure of quality of life such as ADDQOL in combination with more 
responsive generic-measures such SF-36, and monitoring of comorbid 
conditions could aid in doing so. 
In summary, we found quality of life in newly diagnosed Type 2 DM declines 
over six years. This decline was associated with progression of diabetes, 
particularly within the first year. Future work should ideally take the form of a 
long duration prospective cohort study to remove the effect of a trial 
environment. We recommend it uses both disease-specific and generic 
measures of quality of life. Finally, a concurrent qualitative study on a subset of 
the cohort may provide insight into the reasons for this decline and how these 
may be addressed.   
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Chapter 5 – Discussion 
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Summary 
In this project we investigated treatment satisfaction, quality of life, illness 
perception, global life satisfaction and self-esteem in the participants of the 
Early ACTID randomised control trial and its follow up study ACTID Plus. 
Chapter 3 looked at the effects of the trial interventions on these constructs and 
the effects of these constructs on trial outcomes. In Chapter 4 we modelled the 
longitudinal changes in these constructs over six years. We also assessed any 
association between these constructs and progression of Type 2 diabetes as 
defined by increased HbA1c or increased diabetes medication requirement. 
We demonstrated in Chapter 3 that diet and diet plus physical activity 
interventions improved treatment satisfaction in early Type 2 DM. In addition, 
we showed the interventions had no effect on quality of life, illness perception, 
life satisfaction and self-esteem. We also demonstrated the addition of physical 
activity advice to a dietary program did not result in an additional benefit in any 
of these measures. There was also no association between baseline quality of 
life, illness perception, life satisfaction or self-esteem and response to the 
interventions in weight loss or glycaemia. 
We demonstrated in Chapter 4 that quality of life declines over the six years 
following diagnosis of Type 2 DM. This decline was associated with progression 
of diabetes. In addition, we showed there is a modest decline in perceived 
illness threat over this time. The benefits in treatment satisfaction shown in 
Chapter 3 were quickly lost and follow up satisfaction scores quickly returned to 
their baseline level.  
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Conclusions 
Adherence to lifestyle interventions in Type 2 diabetes is poor. Anecdotally, 
there has been suggestions that this is due to the fact sticking to diet and 
physical activity programs can make you unhappy. This is supported by 
research into the barriers to changing lifestyle that has found dieting to be as 
great a burden as insulin treatment and identified barriers to exercise such as 
physical discomfort and stigma, particularly in obese people (23–25). With this 
in mind, the most important finding of this work was that behavioural lifestyle 
interventions delivered in newly diagnosed Type 2 diabetes do not result in 
reduced quality of life, illness perception or psychological wellbeing.   
At the time of the Early ACTID trial there had been increasing calls for physical 
activity to be provided to people with newly diagnosed Type 2 diabetes on a 
large scale. This would require extensive training of healthcare staff at a huge 
cost to the NHS. The main findings of Early ACTID refuted these calls as it 
showed adding physical activity advice to an effective dietary intervention did 
not confer any additional benefits in glycaemia, insulin resistance, weight loss, 
or medication requirement (72). The work presented in this thesis adds further 
weight to this argument by showing there are no benefits in quality of life, 
treatment satisfaction or wellbeing gained by adding physical activity. 
There is concern over whether poor quality of life or psychological wellbeing 
may lead to poor adherence and response to lifestyle interventions delivered 
early in Type 2 diabetes. Anecdotally, there is unease among clinicians about 
asking people who are unhappy or worried to make changes to their lifestyle 
without first addressing these issues. Previous studies have supported this 
notion as depression is associated with poorer adherence to lifestyle 
interventions (56). We were able to address this concern in our study and found 
baseline levels of quality of life, self-esteem and life satisfaction did not 
influence response to the interventions. This provides reassurance to clinicians 
that these interventions can be delivered to everyone, even if they have poorer 
quality of life or psychological wellbeing. However, we did not look at 
depression in our study so we cannot infer from our results that the 
interventions would have remained effective in the context of depression. 
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We have shown that like studies of various diabetes medications, treatment 
satisfaction is significantly improved by diet and diet plus physical activity 
interventions delivered within a trial environment (65). Similar results were also 
seen in the Diabetes X-PERT study of lifestyle interventions in established Type 
2 diabetes (67). In addition to the large improvements seen in the intervention 
arms, there was also a smaller improvement in the treatment satisfaction of 
those receiving usual care. The fact these benefits in all arms were lost after 
participants left the trial highlights the impact improved clinical outcomes and 
involvement in a trial can often have on an individual’s perception of their care.   
There is a paucity of evidence of what happens to the quality of life of people 
with newly diagnosed Type 2 diabetes in the UK. Quality of life is often only 
investigated in interventional trials, often with short follow up. For this reason, 
evidence of the change in quality of life that occurs over the first years following 
diagnosis prior to the development of complications is restricted to one major 
study. The American DPPOS study found quality of life declines slowly over up 
to six years following the diagnosis of Type 2 diabetes (38). Applicability of 
these findings to people with newly diagnosed Type 2 diabetes in the UK is 
limited by the fact it occurred in a very different healthcare system. They were 
also a group of people in whom the diagnosis of diabetes had been made 
despite being made aware of their risk and their best efforts prevent it. We were 
able to show in this thesis that quality of life does indeed decline slowly over the 
six years following diagnosis of Type 2 diabetes.  
Disentangling whether declining quality of life is due to diabetes or simply 
related to aging is difficult. Quality of life is known to decline with age and UK 
population norms for the EQ-5D Index show that health status declines from 
0.91 for those aged under 25 to 0.65 for those aged 65-74 (97). The decline we 
saw of 0.06 over the six years therefore represents a significant drop. Our 
results suggest that this decline is more likely to be due to diabetes, particularly 
early on, as those whose disease progressed during the trial experienced the 
greatest decline in quality of life over the six years. 
Another factor that may influence poor adherence to diabetes is a lack of 
concern for the consequences of the disease, this may in turn lead to quicker 
progression of the disease. We did not find this as perceived illness threat was 
not associated with response to interventions or to disease progression. 
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Perceived illness threat also seems to fall slowly over the six years. This could 
be explained by people gradually coming to terms with their diagnosis of a 
chronic illness and its effects on their daily functioning.  
Finally, Type 2 diabetes can cause people with the disease to feel shame or 
stigma and many people blame themselves for developing the disease (98). As 
a result it can severely impact an individual’s self-worth and self-esteem. 
Reassuringly, life satisfaction and self-esteem appear to be remarkably stable 
over this period. This perhaps suggests these psychological constructs are not 
specifically affected by Type 2 diabetes and may be more associated with 
obesity that would likely pre-exist the development of diabetes. 
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Implications 
The work contained in this thesis has a number of important clinical 
implications. The first is that a reduction in quality of life or wellbeing is not the 
reason for the poor adherence to lifestyle interventions seen in Type 2 diabetes. 
This means we need to look elsewhere for an explanation for the poor 
adherence.   
Secondly, it seems very intensive programs are required to see improvements 
in quality of life and wellbeing. The considerable weight loss seen in the 
intervention arm of the DiRECT randomised control trial of an intensive weight 
management program for the remission of diabetes was associated with 
improved quality of life (22). However, the more modest weight loss in Early 
ACTID was unable to produce an improvement. This adds further to the 
evidence significant weight loss is required to improve quality of life in obese 
individuals (87). 
The confirmation that there is no additional benefit obtained from adding 
physical activity advice to dietary advice has far reaching implications. The 
findings in Early ACTID that both clinical and patient-reported outcomes were 
no different between a diet and diet plus physical activity intervention provides 
clear evidence of the lack of benefit. The implication of this is that if we are to 
improve peoples’ diabetes through lifestyle interventions, the NHS should focus 
on ensuring everyone receives high-quality dietary advice close to diagnosis. 
The fact we found those who progressed quickly within the trial period 
experienced the greatest reduction in quality of life has significant clinical 
implications. The clinical implication of this finding is that if we are to delay the 
decline in quality of life seen in the first years of Type 2 diabetes, then early 
management to delay disease progression is vital. Early intensive dietary 
interventions therefore not only have the ability to improve clinical outcomes but 
have the ability to delay and/or prevent a decline in quality of life. 
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Limitations 
There are some limitations to this work. Many of these were unavoidable, 
particularly as it was carried out on an existing dataset. There are some 
limitations of the original study design that are worth noting. Due to the nature of 
the interventions in Early ACTID it was impossible to blind participants, nurses 
and dietitians to arm allocation which may introduce unwanted biases. This was 
minimised as much as possible by keeping doctors blinded to arm allocation. 
Secondly, making comparisons between the intervention arms is limited by the 
smaller sample size of the usual care arm and the fact that they received 
slightly better care than they would have received in routine clinical practice. 
This is a very practical issue. Recruiting and retaining participants in the usual 
care arm if they did not receive any benefit for their involvement would have 
been difficult and unethical.  
The work in this thesis was also limited by the measures used in Early ACTID. 
The use of EQ-5D to assess quality of life is limited by the fact some believe it is 
better described as a measure of health status, as it does not take into account 
fully an individual’s perception of other aspects outside health (33). In addition, 
it is a generic measure so it makes it more difficult to attribute changes directly 
to diabetes. Perhaps concurrent use of a diabetes-specific measure of quality of 
life would have been ideal.  
We saw a significant ceiling effect in the DTSQ Satisfaction Scores. This a well-
known issue that led to the development of the DTSQ Change version (DTSQc) 
(88). However, the fact we saw an immediate drop in treatment satisfaction after 
completion of the trial provides us with reassurance it remained responsive.  
Whilst self-esteem and global life satisfaction are important components of 
psychological wellbeing, the use of a validated measure of depression would 
have provided important insight into its effect on response to lifestyle 
interventions and on quality of life. These associations have been reported 
elsewhere so would be of great interest in this cohort of newly diagnosed Type 
2 diabetes (40,56). 
The generalisability of our findings is limited by the fact our cohort was not 
ethnically diverse with 96% Caucasian. In addition, the longitudinal changes we 
assessed may have been influenced by lasting effects of participants’ 
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involvement in Early ACTID (the majority in intervention arms). Incomplete 
questionnaire data was a further issue, with just under half of participants (49%) 
completing at least one questionnaire in full at six years. This was not related to 
retention of participants as 82% of those who agreed to be followed up were 
retained after six years, however many of them stopped completing the 
questionnaires. We also saw some slight differences in baseline clinical 
characteristics between those retained at six years and those lost to follow up. 
However, importantly the baseline scores for all of these patient-reported 
measures were similar between the two groups. 
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Future work 
While this thesis answered a number of important questions regarding quality of 
life and wellbeing in newly diagnosed Type 2 diabetes there are many further 
questions that can be answered using this dataset. Modelling of which clinical 
factors had the greatest effect on quality of life and wellbeing would provide 
insight into possible areas that could be the focus for improving quality of life 
and wellbeing in this population. In addition, modelling of the combined clinical 
and patient-reported outcomes may reveal those factors most important in 
determining whether an individuals’ diabetes progresses or doesn’t progress.  
Complete evaluation of the association between diabetes progression and each 
of the measures of quality of life and wellbeing requires complex modelling 
beyond the scope of this work. Questionnaire data in this study represents 
multilevel repeated-measures data, and diabetes progression a survival-type 
binary outcome. Joint modelling allows for simultaneous modelling of the 
repeated measure and survival outcomes and would provide definitive evidence 
of any associations between diabetes progression and quality of life or 
wellbeing (99).  
Patient-reported outcomes are rarely the primary outcome of interventional 
trials. With this in mind, future work on the impact of lifestyle changes in early 
Type 2 diabetes on quality of life and wellbeing should take the form of a 
prospective cohort study. Assessing associations between these measures and 
objectively measured diet and physical activity levels would provide these 
answers. This would remove the issue of usual care representing an 
“enhanced” usual care and the possible lasting impact of interventions on the 
longitudinal change in quality of life and wellbeing seen over the first few years 
following diagnosis of Type 2 diabetes. It should use a combination of generic 
and disease-specific measures of quality of life in order to attempt to isolate the 
effects of diabetes on quality of life. Regarding wellbeing, employing measures 
of depression and diabetes distress would add further to answering whether 
psychological wellbeing is associated with differential response to lifestyle 
changes.  
In the field of interventional trials, patient-reported outcome measures are an 
increasingly important outcome when evaluating new treatments (100). Going 
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forward it is hugely important for measures used in these trials to be 
standardised to maximise meta-analysis and cross comparison. The effects on 
patient reported outcome measures may be small meaning that a meta-analysis 
may be needed to detect these changes. At the moment, this very difficult due 
to the huge variation in patient reported measures used to assess outcomes 
such as treatment satisfaction, wellbeing and quality of life. Thus, there needs 
to be agreement as to which of these patient reported measures should be used 
to assess each specific outcome. 
 
Finally, fundamentally patient-reported outcome measures are limited by the 
fact that they attempt to quantify cognitive and emotional perceptions that are in 
essence very qualitative. Although qualitative studies are not feasible or helpful 
on a large scale, performing concurrent qualitative studies on a subset of study 
cohorts may help to provide insight into the particular factors affecting quality of 
life and wellbeing. These results, in combination with both diabetes-specific and 
generic measures of quality of life, would provide almost definitive evidence of 
the changes in quality and wellbeing that occur in Type 2 diabetes and its 
treatment. 
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Appendix 1: Questionnaires given to participants 
Given exactly as participants received the questionnaires.
116 
 
 
 
 
 
 
 
 
 
 
Wellbeing Questions. 
 
The aim of these questions is to assess how happy you are and how diabetes is 
affecting your life. Please read the instructions for each section very carefully 
as the way in which you need to answer the questions varies. If you have any 
questions please ask the nurse who is conducting the visit. 
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Wellbeing Questions. 
Diener’s Satisfaction with Life Questionnaire : Baseline, 6, 12. 
This is a short, 5-item instrument designed to measure global cognitive judgments of one's lives 
(global life satisfaction). Below are five statements that you may agree or disagree with. Using 
the 1 - 7 scale below indicate your agreement with each item by placing the appropriate number 
in the box preceding that item. 
 
1 - Strongly disagree 
2 - Disagree 
3 - Slightly disagree 
4 - Neither agree nor disagree 
5 - Slightly agree 
6 - Agree  
7 - Strongly agree 
 
 
In most ways my life is close to my ideal. 
 
The conditions of my life are excellent. 
 
I am satisfied with my life. 
 
So far I have gotten the important things I want in life. 
 
If I could live my life over, I would change almost nothing. 
 
 
Rosenberg Self-Esteem Scale : Baseline, 6, 12. 
Below are five statements that you may agree or disagree with. Using a scale of 1 - 4 indicate 
your agreement with each item by placing the appropriate number in the box preceding that item. 
 
(1 = strongly agree, 2 = agree, 3 = disagree, 4 = strongly disagree) 
 
   On the whole I am satisfied with myself 
 
  At times I think I am no good at all 
 
  I feel I have a number of good qualities 
 
  I am able to do things as well as most others 
 
  I feel I don’t have much to be proud of 
 
  I certainly feel useless at times 
 
  I feel I am a person of worth, at least on a plane with others 
 
  I wish I could have more respect for myself 
 
  All-in-all, I’m inclined to feel that I’m a failure 
 
  I take a positive attitude toward myself 
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EQ5D - Baseline, 6, 12. 
 
By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state today. 
 
Mobility 
 
I have no problems in walking about 
 
I have some problems in walking about 
 
I am confined to bed 
 
Self-care 
 
I have no problems with self-care 
 
I have some problems washing or dressing myself 
 
I am unable to wash or dress myself 
 
Usual activities (e.g. work, study, housework, family or leisure activities) 
 
I have no problems with performing my usual activities 
 
I have some problems with performing my usual activities 
 
I am unable to perform my usual activities 
 
Pain/Discomfort 
 
I have no pain or discomfort 
 
I have moderate pain or discomfort 
 
I have extreme pain or discomfort 
 
Anxiety/Depression 
 
I am not anxious or depressed 
 
I am moderately anxious or depressed 
 
I am extremely anxious or depressed 
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Valuing your own health today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
To help people say how good or bad a health 
state is, we have drawn a scale (rather like a 
thermometer) on which the best state you can 
imagine is marked 100 and the worst state you 
can imagine is marked 0.  
 
We would like you to indicate how on this 
scale how good or bad your own health is 
today, in your opinion. Please do this by 
drawing a line from the box below to 
whichever point on the scale indicates how 
good or bad your health state is today. 
 
Your own 
health state 
today 
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DIABETES TREATMENT SATISFACTION QUESTIONNAIRE (DTSQ) 
 
 
The following questions are concerned with the treatment for your diabetes (including insulin, tablets and 
diet) and your experience over the last few weeks.  Please answer each question by circling a number on 
each of the scales. 
 
 
1. How satisfied are you with your current treatment? 
 
 very satisfied  6 5 4 3 2 1 0 very dissatisfied 
 
2 How often have you felt that your blood sugars have been unacceptably high recently? 
 
 most of the time  6 5 4 3 2 1 0 none of the time 
 
3 How often have you felt that your blood sugars have been unacceptably low recently? 
 
 most of the time  6 5 4 3 2 1 0 none of the time 
 
4. How convenient have you been finding your treatment to be recently? 
 
 very convenient   6 5 4 3 2 1 0 very inconvenient 
 
5. How flexible have you been finding your treatment to be recently? 
 
 very flexible  6 5 4 3 2 1 0 very inflexible 
 
6. How satisfied are you with your understanding of  your diabetes? 
 
 very satisfied  6 5 4 3 2 1 0 very dissatisfied 
 
7. Would you recommend this form of treatment to someone else with your kind of diabetes? 
 
 Yes, I would   6 5 4 3 2 1 0 No, I would definitely   
     definitely not 
 recommend the         recommend the  
 treatment         treatment 
 
8. How satisfied would you be to continue with your present form of treatment? 
 
 very satisfied  6 5 4 3 2 1 0 very dissatisfied 
 
Please make sure that you have circled one number on each of the scales. 
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BRIEF Illness Perception Questionnaire - Baseline, 6, 12. 
The following questions look at how you perceive your diabetes, please circle the number that best 
corresponds to your views: 
  
How much does your illness affect your life? 
 0  1 2 3 4 5 6 7 8 9  10  
no affect at all            severely affects my life 
             
How long do you think your illness will continue? 
 0  1 2 3 4 5 6 7 8 9  10  
a very short time            forever 
             
How much control do you feel you have over your illness? 
 0  1 2 3 4 5 6 7 8 9  10  
absolutely no control            extreme amount of control 
             
How much do you think your treatment can help your illness? 
 0  1 2 3 4 5 6 7 8 9  10  
not at all            extremely helpful 
             
How much do you experience symptoms from your illness? 
 0  1 2 3 4 5 6 7 8 9  10  
no symptoms at all            many severe symptoms 
             
How concerned are you about your illness? 
 0  1 2 3 4 5 6 7 8 9  10  
not concerned at all            extremely concerned 
             
How well do you feel you understand your illness? 
 0  1 2 3 4 5 6 7 8 9  10  
don’t understand at all            understand very clearly 
             
How much does your illness affect you emotionally? (eg. does it make you angry, scared, upset or 
depressed?) 
 0  1 2 3 4 5 6 7 8 9  10  
not at all affected 
emotionally 
           extremely affected 
emotionally 
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Please list in rank-order the three most important factors that you believe caused your illness. The most 
important causes for me:- 
 
1. ________________________________________________________________ 
2. ________________________________________________________________ 
3. ________________________________________________________________ 
 
 
